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STABLE BACTERIAL CULTURES FOR 
PRODUCING ALGINATES 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of the filing date of U.S. 
Provisional Patent Application No. 61/048,858, filed Apr. 29, 
2008, which is incorporated herein by reference in its entirety. 
STATEMENT REGARDING 
FEDERALLY-SPONSORED RESEARCH AND 
DEVELOPMENT 
Statement under MPEP 310. The U.S. government and the 
West Virginia State government have a paid-up license in this 
invention and the right in limited circumstances to require the 
patent owner to license others on reasonable terms as pro-
vided for by the terms of NNA04CC74G awarded by the 
National Aeronautics and Space Administration (NASA) and 
the research grants awarded by the NASA West Virginia 
Space Grant Consortium. 
Part of the work performed during development of this 
invention utilized U.S. Government and the State West Vir-
ginia funds. The U.S. Government and West Virginia govern-
ment have certain rights in this invention. 
REFERENCE TO A SEQUENCE LISTING 
SUBMITTED ELECTRONICALLY VIA EFS-WEB 
The content of the electronically submitted sequence list-
ing (Name: sequence listings.ascii.txt, Size: 10 kilobytes; and 
Date of Creation: Aug. 4, 2009) filed with the application is 
incorporated by reference in its entirety. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to methods for alginate pro-
duction using mucoid bacterial cultures. The present inven-
tion also provides for pharmaceutical compositions that con-
tain bacterial alginate. The bacterial alginate may be 
produced using genetically engineered bacteria. 
2. Background Art 
Alginate 
Alginates are salts of alginic acid, which is a linear hetero-
polysaccharide. Alginates are comprised of two subunits, 
P-D-mannuronic acid (denoted M units) and a-L-guluronic 
acid (denoted G units). Alginates may be found in and iso-
lated from various species, in particular from algae belonging 
to the order Phaeophyceae and soil bacteria such as Azoto-
bacter vinelandii andAzotobacter crococcum. Common algal 
sources of alginates include Laminaria digitata, Ecklonia 
maxima, Macrocystis pyrifera, Lessonia nigrescens, Asco-
phyllum nodosum, Laminaria japonica, Durvillea antartica, 
Durvillea potatorum and Laminaria hyperborea. 
Alginates produced from various sources differ consider-
ably in their structure. For example, alginates produced by 
seaweed are generally not acetylated, whereas bacteria pro-
duce alginates with a higher degree of acetylation. In addi-
tion, the molecular weight and the ratio of P-D-mannuronic 
acid and a-L-guluronic acid units in alginates can vary based 
on the alginate source and the conditions in which the alginate 
is produced. These structural differences can result in 
changes in alginate properties. 
Alginates are commonly purified from brown seaweeds. 
However, brown seaweed is a limited resource and extraction 
of alginate results in destruction of this precious resource. In 
addition, there are several problems associated with seaweed 
alginate. First, their harvest is seasonal and alginate produc-
tion is dependent on cold ocean temperature, which is rising, 
5 most likely due to global warming. Second, extraction of 
seaweed alginate involves as many as 15-20 different pro-
cessing steps. Third, the composition of the alginate produced 
by the seaweed is fixed and cannot be altered to produce a 
better or different product to expand commercial applica- 
io tions. 
Alginate can be used in a wide variety of products. For 
example, seaweed alginates are used in food, dental and cos-
metic products. The alginates are particularly useful as gel-
ling, thickening, stabilizing, swelling and viscosity imparting 
15 agents. Seaweed alginate is used in the textile and paper 
industries and also serves as a thickening agent in common 
food items, such as ice cream, salad dressing, pet food 
chunks, low fat spreads, sauces and pie filings. Seaweed 
alginate is also incorporated into wound dressings to provide 
20 a moist surface for healing. Alginate fibers trapped in a wound 
are readily biodegraded. Dressings with seaweed alginate are 
used to treat ulcers in diabetic patients. Propylene glycol 
alginate has been used as an acid-stable stabilizer for uses 
such as preserving the white fluffy head of foam on beers. 
25 Seaweed alginate absorbs radioactive elements, heavy metals 
and free radicals. Because alginate cannot be broken down by 
bile or saliva and cannot be absorbed by the body, it is secreted 
from the body together with the heavy metals and radioactive 
substances. The ever-increasing applications of this biopoly- 
30 mer have led to continued interest in better understanding the 
biosynthesis pathway and regulatory mechanisms as well as 
optimization of microbial production process. 
Regulation of Alginate Production Pathway in Pseudomonas 
Synthesis of alginate and its regulation has been the object 
35 of numerous studies (Govan, J. R., and V. Deretic, Microbiol. 
Rev. 60:539-74 (1996); Ramsey, D. M., and D. J. Wozniak, 
Mol. Microbiol. 56:309-22 (2005)). Alginate production is 
positively and negatively regulated in wild-type cells of 
Pseudomonas. 
40 Three tightly linked genes algU, mucA, and mucB have 
been identified with a chromosomal region shown by genetic 
means to represent the site where mutations cause conversion 
to mucoidy (see U.S. Pat. Nos. 6,426,187, 6,083,691, 5,591, 
838, and 5,573,910, incorporated herein by reference in their 
45 entireties). 
Positive regulation centers on the activation of the alginate 
biosynthetic operon (Govan, J. R., and V. Deretic, Microbiol. 
Rev. 60:539-74 (1996)). Positive regulators include the alter-
native stress-related sigma factorAlgU (Martin, D. W., et al., 
50 Proc. Natl. Acad. Sci. 90:8377-81 (1993)), also called A1gT 
(DeVries, C. A., and D. E. Ohman, J. Bacteriol. 176:6677-87 
(1994)), and transcriptional activators A1gR andAlgB, which 
belong to a bacterial two component signaling system. The 
cognate kinase ofA1gB is KinB (Ma, S., et al., J. Biol. Chem. 
55 272:17952-60 (1997)) whileAlgZ (Yu, H., et al., J. Bacteriol. 
179:187-93 (1997)) may be the kinase that phosphorylates 
A1gR. However, unlike a typical two-component system, 
alginate overproduction is independent of phosphorylation of 
A1gR or A1gB (Ma, S., et al., J. Bacteriol. 180:956-68 
60 (1998)). 
Negative regulation of alginate has focused on the post-
translational control of A1gU activity. In alginate regulation, 
the master regulator is A1gU and the signal transducer is 
MucA, a trans-inner membrane protein whose amino tenni- 
65 nus interacts with A1gU to antagonize the activity of A1gU, 
and the carboxyl terminus with MucB, another negative regu-
lator of alginate biosynthesis. The algUmucABC cluster is 
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conserved among many Gram-negative bacteria. A1gU 
belongs to the family of extracytoplasmic function (ECF) 
sigma factors that regulate cellular functions in response to 
extreme stress stimuli. The action of ECF sigma factors is 
negatively controlled by MucA, MucB and MucC. This set of 
proteins forms a signal transduction system that senses and 
responds to envelope stress. 
MucA is the anti-sigma factor that binds A19U and antago-
nizes its transcriptional activator activity (Schurr, M. 7., et al., 
J. Bacteriol. 178:4997-5004 (1996)). Consequently, inactiva-
tion of mucA in P. aeruginosa strain PAOI results in the 
mucoid phenotype (Alg+) (Martin, D. W., et al., Proc. Natl. 
Acad. Sci. USA 90:8377-81 (1993); Mathee, K., et al., Micro-
biology 145:1349-57 (1999)). Clinical mucoid isolates of P. 
aeruginosa carry recessive mutations in mucA (Anthony, M., 
et al., J. Clin. Microbiol. 40:2772-8 (2002); Boucher, J. C., et 
al., Infect. Immun. 65:3838-46 (1997)). The transition from a 
non-mucoid to mucoid variant occurs in concurrence with the 
mucA22 allele after exposure to hydrogen peroxide, an oxi-
dant in neutrophils (Mathee, K., et al., Microbiology 145: 
1349-57 (1999)). 
MucB is located in the periplasm in association with the 
periplasmic portion of MucA (Mathee, K., et al., J. Bacteriol. 
179:3711-20 (1997); Rowen, D. W., and V. Deretic, Mol. 
Microbiol. 36:314-27 (2000)). MucC is a mild negative regu-
lator whose action is not completely understood, but thought 
to be in synergy with MucA and/or MucB (Boucher, J. C., et 
al., Microbiology 143:3473-80 (1997)). MucD is a negative 
regulator whose dual functions include periplasmic serine 
protease and chaperone activities that are thought to help 
remove misfolded proteins of the cell envelope for quality 
control (Boucher, J. C., et al., J. Bacteriol. 178:511-23 
(1996);Yorgey, P., etal.,Mol. Microbiol. 41:1063-76 (2001)). 
Alginate Production in Pseudomonas 
Alginate production in mucoid strains of P. aeruginosa has 
been limited because these strains quickly convert to non-
mucoid strains and do not produce sufficient amounts of 
alginate for commercial application. Other species of 
Pseudomonas generally produce small amounts of alginates, 
or alginates of low molecular weight. In spontaneous algi-
nate-producers, non-mucoid revertants tend to arise fre-
quently (Flynn and Ohman, J. Bacteriol. 170:1452-1460 
(1988)). 
Non-pathogenic species ofPseudomonas such asP.. putida, 
P. mendocina and P. fluorescens produce exopolysaccharides 
similar to acetylated alginates. (Govan J. R. W. et al., J. of 
General Microbiology 125:217-220 (1981)). Conti et al. also 
describe production of alginates from P. fluorescens and P. 
putida. (Conti, E. et al., Microbiology 140:1125-1132 
(1994)). However, these strains produce small quantities of 
alginate. 
There is therefore a need for suitable bacterial sources and 
methods for inexpensive mass production of alginate. In par-
ticular, there is a need for bacterial sources producing large 
amounts of high quality alginate with defined structure and 
desired molecular weight. 
BRIEF SUMMARY OF THE INVENTION 
The present invention describes methods of alginate pro-
duction in mucoid bacteria, biological cultures for alginate 
production, and compositions that contain alginate produced 
by mucoid bacteria. Bacterial alginates are also described. 
In one embodiment of the invention, the invention provides 
a method for producing alginate comprising culturing mucoid 
bacteria and isolating alginate, wherein the mucoid bacteria 
have increased MucE activity. 
4 
The present invention is also directed to methods for pro-
ducing alginate comprising culturing mucoid bacteria and 
isolating alginate, wherein the mucoid bacteria have 
decreased MucA activity. In some embodiments, the 
5 decreased MucA activity is the result of a transposon inser-
tion. In some embodiments, the transposon insertion is 
upstream of the mucA coding sequence. In some embodi-
ments, the decreased MucA activity is the result of a mutation 
that results in a truncated MucA protein. 
l0 	 The present invention is also directed to a method for 
producing alginate comprising culturing mucoid bacteria and 
isolating alginate, wherein the mucoid bacteria have 
increased C1pP, C1pP2 and/or C1pX protease activity. 
15 The present invention is also directed to a method for 
producing alginate comprising culturing mucoid bacteria and 
isolating alginate, wherein the mucoid bacteria have 
decreased MucD activity. 
The present invention is further directed to a method for 
20 producing alginate comprising culturing mucoid bacteria and 
isolating alginate, wherein the mucoid bacteria are stable for 
at least two weeks. 
The present invention is also directed to a method for 
producing alginate comprising culturing mucoid bacteria and 
25 isolating alginate, wherein the mucoidbacteria do not express 
at least one endotoxin gene. 
Additionally, the present invention is directed to a biologi-
cal culture comprising stable mucoid bacteria that produce 
alginate wherein the bacteria have increased MucE activity. 
30 In some embodiments, the biological culture comprises 
stable mucoid bacteria that produce alginate wherein the bac-
teria have increased C1pP, C1pP2 and/or C1pX protease activ-
ity. In some embodiments, the biological culture comprises 
35 stable mucoid bacteria that produce alginate wherein the bac-
teria have decreased MucA activity. In some embodiments, 
the invention is directed to a biological culture comprising 
stable mucoid bacteria that produce alginate wherein the bac-
teria are stable for at least two weeks. In some embodiments, 
40 the biological culture comprises stable mucoid bacteria that 
produce alginate wherein the bacteria do not express at least 
one endotoxin gene. 
The present invention is also directed to a composition 
comprising alginate wherein the alginate is produced by a 
45 stable bacterial culture that has increased MucE activity. In 
some embodiments, the invention is directed to a composition 
comprising alginate wherein the alginate is produced by a 
stable bacterial culture that has increased C1pP, C1pP2, and/or 
C1pX activity. In some embodiments, the composition com- 
50 prises alginate wherein the alginate is produced by a stable 
bacterial culture that has decreased MucA activity. In some 
embodiments, the composition comprises alginate wherein 
the alginate is produced by a bacterial culture that is stable for 
at least two weeks. In some embodiments, the composition 
55 comprises alginate wherein the alginate is produced by a 
stable bacterial culture that does not express at least one 
endogenous endotoxin gene. In some embodiments, the algi-
nate in the composition is at least 90% pure. 
In some embodiments of the present invention, the stable 
60 mucoid bacteria is P. aeruginosa. In some embodiments of 
the present invention, the P. aeruginosa are cultured at 37° C. 
In some embodiments of the present invention, the alginate is 
acylated and the degree of acetylation is about 0.1 to 1.0. In 
some embodiments, the ratio of M blocks to G blocks in the 
65 alginate is between about 1:10 to 10:1. In some embodiments, 
the alginate has a molecular weight of between about 500 and 
20,000 kD. In some embodiments, the alginate has a viscosity 
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between about 10 and 500 dL/g. In some embodiments, the 
alginate has a hydrodynamic radius between about 50 and 
500 mu. 
BRIEF DESCRIPTION OF THE 
DRAWINGS/FIGURES 
The following drawings form part of the present specifica-
tion and are included to further demonstrate certain aspects of 
the present invention. The invention may be better understood 
by reference to one or more of these drawings in combination 
with the detailed description of specific embodiments pre-
sented herein. 
FIG. 1 shows a schematic diagram depicting the transpo-
sition by the himarl mariner transposon of pF AC in 
Pseudomonas aeruginosa nonmucoid reference strain PAOI 
(FIG. 1A) and schematics showing three genetic clusters that 
regulate the mucoid phenotype identified via the himarl 
mariner transposon mutagenesis in wild-type PAOI (FIG. 
113-D). In FIG. 1A, the 5'TA3' dinucleotide on the chromo-
some is underlined, and the following abbreviations are used: 
IR, inverted repeat; GmR , the gentamicin resistance marker 
(aacCI); P, m , the d' dependent promoter of aacCl. 
GM5OUT and GM3OUT are DNA primers specifically 
designed for inverse PCR (iPCR). Restriction digestion sites 
that can be used for iPCR are denoted: K, Kpn I; S, Sal I; H, 
Hind III; E, EcoR I; P, Pst I; and Sm, Sma I. The nucleic acid 
sequences of the 57A3' dinucleotide and inverted repeat 
regions of the himarl mariner transposon are provided in 
SEQ ID NOS: 11 and 12, respectively. FIGS. 113, 1C and 1D 
show the a1gU mucABCD, the mucE, and the a1gB king 
regions respectively. Open circles represent the sites of trans-
poson insertions. The arrows indicate the directions of tran-
scription driven by the transposon-derived promoter (P, m). 
The numbers below the gene represent the corresponding 
positions on the annotated PAOI genome. Designations of 
VE, V and DR refer to the mucoid mutants generated in the 
backgrounds of PAOL PAO57NM and PA14, respectively. 
FIG. 2 shows alginate production by an a1gU strain, 
mucABCD strains and wild-type P. aeruginosa PAOL 
Amounts of alginate (µg alginate/mg protein) were measured 
from 4-72 hours. Asterisk indicates significant differences at 
P<0.05 in comparison with the same time point in wild-type 
PAOI (t test). The genotype of each mutant is shown. The +oe 
superscript used in panel B refers to the overexpression of the 
a1gU-mucABC operon. Bacterial cells were grown on PIA 
plates and incubated at 37° C. for 4-72 hours. 
FIG. 3 shows alginate production in a mucE and kinB strain 
in comparison with the wild-type PAO1 . The +oe superscript 
used in panel B refers to the overexpression of the mucE. 
FIG. 4 shows alginate production in the P. aeruginosa 
wild-type and mutant strains. Genetic complementation tests 
were performed using pUCP20 vector (negative control) and 
with pUCP20 vector containing c1pP2, fig, c1pX or c1pP 
sequences. 
FIG. 5 shows western blot analysis of N-terminal HA-
tagged MucA25 protein in P. aeruginosa. Lane 1: PAOI/ 
pUCP20T-pBAD (vector control). Lanes 2-7: HA-MucA25 
was expressed from pUCP20T-PIIDmucA25 under the 
induction of 0.05% arabinose. Rabbit polyclonal antibody 
against the P. aeruginosa RNA polymerase a-subunit 
(RNAP) was used as a loading control. 
FIG. 6 shows a schematic diagram for the mucA25 muta-
tion-causedmucoid phenotype in P. aeruginosa PAO581 and 
the cytoplasmic proteolysis involved in the regulation of algi-
natebiosynthesis. The singlebase deletion of T180 resulted in 
a premature stop codon in mucA and C-terminal truncation of 
6 
MucA to MucA25. This truncation is before the transmem-
brane domain (84-104) of wt MucA but the cellular localiza-
tion of MucA25 has yet to be proven. The truncated N-tenni-
nus of MucA25 is subjected to proteolysis by C1pXP and 
5 C1pP2, leading to the release of the sequestered A1gU to drive 
transcription of the alginate biosynthesis operon of algD-A. 
FIG. 7 shows an alignment of the mucE homologs identi-
fied from the completed and partially completed genomes of 
three species within the genus of Pseudomonas. The three 
10 species are PA: Pseudomonas aeruginosa; PF: Pseudomonas 
fluorescens; and PS: Pseudomonas syringae. The strains 
shown are: PA-PAOI (SEQ ID NO: 4), Pseudomonas aerugi-
nosa PAOI (causes opportunistic infections in humans); PA-
PA14 (SEQ ID NO: 3), Pseudomonas aeruginosa UCBPP 
15 PA14 (human clinical isolate); PA-2192 (SEQ ID NO: 1), 
Pseudomonas aeruginosa 2192 (CF patient isolate); 
PA-C3719 (SEQ ID NO: 2), Pseudomonas aeruginosa 
C3719 (unknown source but probably clinical origin); PS-
PPH (SEQ ID NO: 7), Pseudomonas syringae pv. phaseoli- 
20 cola 1448A (causes halo blight on beans); PS-PTO (SEQ ID 
NO: 8), Pseudomonas syringae pv. tomato DC3000 (bacterial 
speck disease on tomato plants); PS-SB728 (SEQ ID NO: 9), 
Pseudomonas syringae pv. syringae B728a (brown spot dis-
ease on beans); PF-PF5 (SEQ ID NO: 5), Pseudomonas fluo- 
25 rescens Pf-5 (Saprophyte) (the production of a number of 
antibiotics as well as the production of siderophores by this 
strain can inhibit phytopathogen growth); and PF-PFOI 
(SEQ ID NO: 6), Pseudomonas fluorescens NO-1 (microor-
ganism of putrefaction and well adapted to soil environ- 
30 ments). SEQ ID NO: 10 provides the mucE consensus 
sequence for Pseudomonas. 
FIG. 8 shows colony morphologies on a PIA plate after 
growth at 37° C. for 24 hours of the reference strain of P. 
aeruginosa PAOL mucoid variant PAO581 (PAOI mucA25), 
35 and null mutants of tig (PAO581DR23), c1pP 
(PAO581DR58), c1pX (PAO581DR45) and c1pP2 
(PA0581 DR3). 
FIG. 9 shows a schematic of wild-type and mutant MucA 
proteins. 
40 	 FIG. 10 shows the genetic construction of the alginate 
producing strain HD101. 
DETAILED DESCRIPTION OF THE INVENTION 
45 	 Definitions 
The term "positive regulator" as used herein, means that 
the induction of expression and/or activity of a gene encoding 
a functional protein causes alginate overproduction. 
5o Examples of positive regulators include a1gU, mucE, and 
algW. 
The term "negative regulator" as used herein, means that 
the absence of such a gene encoding a functional protein 
causes alginate overproduction. Examples of negative regu- 
55 lators include kinB, mucA, mucB, and mucD. 
The term "recombinant," as used herein, means that a pro-
tein is derived from recombinant (e.g., microbial) expression 
systems. The term "microbial" refers to recombinant proteins 
made in bacterial or fungal (e.g., yeast) expression systems. 
6o As a product, the term "recombinant microbial" defines a 
protein produced in a microbial expression system which is 
essentially free of native endogenous substances (e.g., gly-
can). Protein expressed in most bacterial cultures, e.g., E. 
coli, will be free of glycan. 
65 The term "DNA sequence" refers to a DNA polymer, in the 
form of a separate fragment or as a component of a larger 
DNA construct. Preferably, the DNA sequences are in a quan- 
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tity or concentration enabling identification, manipulation, 
and recovery of the sequence and its component nucleotide 
sequences by standard biochemical methods, for example, 
using a cloning vector. Such sequences are preferably pro-
vided in the form of an open reading frame uninterrupted by 5 
internal nontranslated sequences. Genomic DNA containing 
the relevant sequences could also be used. Sequences of non-
translated DNA may be present 5' or 3' from the open reading 
frame, where the same do not interfere with manipulation or 
expression of the coding regions. 10 
The term "nucleotide sequence" refers to a heteropolymer 
of deoxyribonucleotides. DNA sequences encoding the pro-
teins of this invention can be assembled from fragments and 
short oligonucleotide linkers, or from a series of oligonucle-
otides, to provide a synthetic gene which is capable of being 15 
expressed in a recombinant transcriptional unit. 
The term "recombinant expression vector" refers to a rep-
licable DNA construct used either to amplify or to express 
DNA which encodes the recombinant proteins of the present 
invention and which includes a transcriptional unit compris- 20 
ing an assembly of (1) a genetic element or elements having 
a regulatory role in gene expression, for example, promoters 
or enhancers, (2) a structure or coding sequence which is 
transcribed into mRNA and translated into protein, and (3) 
appropriate transcription and translation initiation and tenni- 25 
nation sequences. Structural elements intended for use in 
yeast expression systems preferably include a leader 
sequence enabling extracellular secretion of translated pro-
teinby a host cell. Alternatively, where recombinant protein is 
expressed without a leader or transport sequence, it may 30 
include an N-terminal methionine residue. This residue may 
optionally be subsequently cleaved from the expressed 
recombinant protein to provide a final product. 
As used herein, the term "expression vector" refers to a 
construct made up of genetic material (i.e., nucleic acids). 35 
Typically, a expression vector contains an origin of replica-
tion which is functional in bacterial host cells, e.g., Escheri-
chia coli, and selectable markers for detecting bacterial host 
cells comprising the expression vector. Expression vectors of 
the present invention contain a promoter sequence and 40 
include genetic elements as described herein arranged such 
that an inserted coding sequence can be transcribed and trans-
lated in prokaryotes or eukaroytes. In certain embodiments 
described herein, an expression vector is a closed circular 
DNA molecule. The term "plasmid" is used interchangeably 45 
with "expression vector." 
The term "expression" refers to the biological production 
of a product encoded by a coding sequence. In most cases, a 
DNA sequence, including the coding sequence, is transcribed 
to form a messenger-RNA (mRNA). The messenger-RNA is 50 
then translated to form a polypeptide product which has a 
relevant biological activity. Also, the process of expression 
may involve further processing steps to the RNA product of 
transcription, such as splicing to remove introns, and/or post-
translational processing of a polypeptide product. The term 55 
"overexpress" or "overexpression" refers to a biological 
product that is transcribed or translated at a rate higher, is 
more stable than that in wild-type strains and/or is more active 
than that in wild-type strains. 
The term "recombinant microbial expression system" 60 
means a substantially homogeneous monoculture of suitable 
host microorganisms, for example, bacteria such as E. coli or 
yeast such as S. cerevisiae, which have stably integrated a 
recombinant transcriptional unit into chromosomal DNA or 
carry the recombinant transcriptional unit as a component of 65 
a resident plasmid. Generally, cells constituting the system 
are the progeny of a single ancestral transformant. Recombi- 
8 
nant expression systems as defined herein will express heter-
ologous protein upon induction of the regulatory elements 
linked to the DNA sequence or synthetic gene to be 
expressed. 
As used herein, the term "biological functional equivalent" 
refers to proteins which contain modifications or changes in 
the structure of the coding region, but still result in a protein 
molecule having like or otherwise desirable characteristics. 
For example, certain amino acids may be substituted for other 
amino acids in a protein structure without appreciable loss of 
interactive binding capacity with structures such as, for 
example, antigen-binding regions of antibodies or binding 
sites on substrate molecules. Since it is the interactive capac-
ity and nature of a protein that defines that protein's biological 
functional activity, certain amino acid sequence substitutions 
can be made in the DNA coding sequence and nevertheless 
obtain a protein with like or even counterveiling properties 
(e.g., antagonistic v. agonistic). It is thus contemplated by the 
inventors that various changes may be made in the DNA 
sequence of proteins or peptides without appreciable loss of 
their biological utility or activity. 
As used herein, the term "comprising" means including the 
steps or elements that are identified following that term, but 
any such steps or elements are not exhaustive, and an embodi-
ment may include other steps or elements. 
Alginate 
Alginates are comprised of two subunits: P-D-mannuronic 
acid (denoted M units) and a-L-guluronic acid (denoted G 
units). Alginic acid and alginates of the present invention may 
comprise homopolymeric sequences of mannuronic acid, 
known as M blocks, homopolymeric sequences of guluronic 
acid, known as G blocks, and mixed sequences ofmannuronic 
acid and guluronic acid units, known as MG blocks or alter-
nating blocks. Alginate of the present invention may contain 
the following structure of an alginate chain. The structure 
includes an M block, a G block and an MG block followed by 
a G block: 
Alginates of the present invention may contain all three 
different blocks and each block may contain from about three 
to about twenty monomer (M or G) units. The distribution of 
the M, G and MG blocks and also the relative quantity of the 
M and G units can vary. The ratio of M and G units and/or 
blocks can vary depending on the growth conditions and 
bacterial strain used. High ratios ofM block to G block result 
in highly viscous solutions. 
In some embodiments of the present invention, the alginate 
can have a particular ratio of M blocks to G blocks. For 
example, the ratio of M blocks to G blocks can be between 
1:10 or 10:1. Alginate with a ratio of M blocks to G blocks of 
between 1:10 and 1:1 and alginate with a ratio of M blocks to 
G blocks of between 1:1 and 1:10 are also contemplated. In 
some embodiments, the ratio of M blocks to G blocks is about 
2:1, 3:1, 4:1 or about 5:1. In some embodiments, the ratio of 
M blocks to G blocks is between 2:1 and 3:1, between 3:1 and 
4:1 or between 4:1 and 5:1. 
In other embodiments of the invention, the alginate can 
have a particular percentage of M and G units. In some 
embodiments, the alginate contains at least 50% M units, at 
least 60% M units, at least 70% M units, at least 80% M units, 
at least 90% M units, or at least 95% M units. In other 
embodiments of the invention, the alginate has between 50 
and 60% M units, between 60 and 70% M units, between 70 
and 80% M units or between 80 and 90% M units. In some 
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embodiments, the alginate contains at least 50% G units, at 
least 60% G units, at least 70% G units, at least 80% G units, 
at least 90% G units, or at least 95% G units. In other embodi-
ments of the invention, the alginate has between 50 and 60% 
G units, between 60 and 70% G units, between 70 and 80% G 5 
units or between 80 and 90% G units. 
The M/G ratio can be determined using any method known 
in the art. For example, the M/G ratio can be determined using 
the crude carbazole analysis on the content of uronic acid with 
D-mannuronic acid lactone as the standard (Knutson, C. A., io 
and A. Jeans, Anal. Biochem. 24:470-481 (1968)). This ratio 
can also be more precisely determined with a high-perfor-
mance liquid chromatographic (HPLC) method as described 
in Sanchez-Machado, D. I., et al., Biomed Chromatogr. 
18:90-97 (2004)). 15 
Molecular weight is another characteristic of alginate. As 
the polymeric chain increases in length and therefore 
increases in molecular weight, the alginatebecomes less elas-
tic. High molecular weight alginate results in increased vis-
cosity. The molecular weight can vary based on how the 20 
alginate is produced and/or purified. The molecular weight of 
alginate purified from seaweed varies, but is generally 
between 70 and 80 kD. In contrast, the molecular weight of 
alginate produced from bacteria is generally about 500 kD. 
In some embodiments of the present invention, the alginate 25 
has a particular molecular weight. For example, in some 
embodiments, the alginate has an average molecular weight 
of about 500 kD, 600 kD, 700 kD, 800 kD, 900 kD, 1000 kD, 
5000 kD, 10,000 kD or about 15,000 kD. In some embodi-
ments of the invention, the average molecular weight of the 30 
alginate is between about 500 and 1000 kD, 1000 and 10,000 
kD, 10,000 and 20,000 kD, 10,0000 and 15,0000 kD or 
between about 15,000 and 20,000 kD. In some embodiments 
of the invention, the average molecular weight of the alginate 
is between about 500 and 10,000 kD, 500 and 20,000 kD, 500 35 
and 15,0000 kD or between about 500 and 20,000 kD. 
The molecular weight of the alginate can be determined 
using any method known in the art. For example, molecular 
weight can be determined using art-known technologies and 
technologies including, but not limited to, Gel Permeation 40 
Chromatography (GPC), Flow Injection Polymer Analysis 
(FIPA), Dilute Solution Viscosity (DSV) and Dynamic Light 
Scattering (DLS). The molecular weight can also be deter-
mined, for example, by using the Viscotek Triple Detector 
System (Houston, Tex.), which utilizes multiple technologies 45 
including the intrinsic viscosity (dL/g; essentially the inverse 
density) and Low Angle Light Scattering to measure poly-
mers with large molecular weights, such as 10 million Dalton. 
While older technologies utilizing multi-angle light scatter-
ing detectors (using a lowest usable angle of about 35 50 
degrees) can introduce an error of 60%, Viscotek's Low 
Angle Light Scattering detector introduces an approximate 
2% error rate in molecular weight calculation, thus allowing 
for a more precise determination of the molecular weight of 
bacterial alginate. 55 
Acetylation, i.e. the addition of acetyl groups, can also 
affect the properties of alginates and varies based on methods 
of production and purification used. Bacterially produced 
alginates may be O-acetylated on the C-2 and C-3 carbons of 
mannuronic acid residues, and the degree of acetylation may 60 
vary. The degree of acetylation is generally expressed as the 
number of acetyl groups per monomer. For example, a degree 
of acetylation of 0.5 indicates an average of 1 acetyl group per 
2 monomers. In some embodiments of the invention, the 
alginate has a particular degree of acetylation. For example, 65 
in some embodiments, the degree of acetylation is about 0.1, 
about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7,  
10 
about 0.8, about 0.9, about 1.0, or about 2.0. In other embodi-
ments of the invention, the degree of acetylation is between 
about 0.1 and 0.3, 0.3 and 0.5, 0.5 and 0.7, 0.7 and 0.9 or 
between about 0.9 and 1.0. 
The properties of alginate can also be affected by its hydro-
dynamic radius. The hydrodynamic radius is the radius as 
calculated by the diffusional properties of the particles. It is 
indicative of the apparent size of the particle. In some 
embodiments of the invention, the alginate has a particular 
hydrodynamic radius. For example, the hydrodynamic radius 
can be about 10 mu, about 50 mu, about 100 mu, about 150 
mu, about 200 mu, about 250 nm or about 300 mu. In some 
embodiments of the invention, the hydrodynamic radius is 
between about 50 and 500 mu, 100 and 500 mu, 200 and 500 
mu, 100 and 400 mu, 200 and 400 nm or between about 250 
and 350 mu. The hydrodynamic radius can also be between 
about 50 and 100 mu, 50 and 150 mu, 50 and 200 mu, 50 and 
250 mu, 50 and 300 mu, 50 and 400 mu, 50 and 500 nm or 
between about 50-1000 mu. The hydrodynamic radius can be 
measured using any technique known in the art, including for 
example, by dynamic light scattering. 
Another feature of alginate is its viscosity. Viscosity is 
affected by, for example, a combination of molecular weight, 
M:G ratios and/or acetylation. In some embodiments of the 
present invention, the alginate has a particular viscosity. For 
example, in some embodiments, the viscosity is about 5 dL/g, 
about 10 dL/g, greater than 20 dL/g, about 30 dL/g, about 40 
dL/g, about 50 dL/g, about 60 dL/g, about 70 dL/g, about 80 
dL/g, about 90 dL/g, about 95 dL/g, about 96 dL/g, about 97 
dL/g, or about 98 dL/g. In some embodiments, the viscosity is 
between about 10 and 500 dL/g, 25 and 250 dL/g, 50 and 200 
dL/g, 75 and 150 dL/g, 80 and 125 dL/g, 90 and 110 dL/g, 95 
and 105 dL/g, 96 and 98 dL/g or between about 95 and 100 
dL/g. Viscosity can be measured using any method known in 
the art. For example, viscosity can be measured as the intrin-
sic viscosity (IV) using Viscotek Corp. technologies. IV is 
defined as a direct measurement of the amount of volume 
occupied by a gram of fully solvated molecules in solution, 
which essentially describes the molecular size of bacterial 
alginates in solution. 
The amount of alginate produced by the strains of the 
present invention is as high as about 100 g per liter of broth 
(g/L), 90 g/L, 80 g/L, 70 g/L, 60 g/L, 50 g/L, 40 g/L, 30 g/L, 
20 g/L, 18 g/L, 16 g/L, 14 g/L, 12 g/L, 10 g/L, 8 g/L, 6 g/L, or 
about 4 g/L. The minimum amount of alginate produced by 
the strains of the present invention is about 2 g/L. In some 
embodiments, the amount of alginate produced by the strains 
of the present invention is about 2 to 100 g/L, 1 to 80 g/L, 2 to 
60 g/L, 2 to 40 g/L, 2 to 20 g/L or about 2 to 10 g/L. In some 
embodiments, the amount of alginate produced by the strains 
of the present invention is about 10 to 100 g/L, 10 to 80 g/L, 
10 to 60 g/L, 10 to 40 g/L or about 10 to 20 g/L. In some 
embodiments of the invention, the amount of alginate pro-
duced by the strains of the present invention is about 2 to 20 
g/L, 20 to 40 g/L, 40 to 60 g/L, 60 to 80 g/L or about 80 to 100 
g/L. 
Methods and Cultures for Producing Alginate in Bacteria 
The present invention provides methods for producing 
alginate comprising culturing mucoid bacteria. According to 
the present invention, alginate can be produced by any 
mucoid bacteria. In one embodiment of the invention, algi-
nate is produced by gram-negative bacteria, for example, by 
bacteria of the genus Pseudomonas or Azotobacter. Accord-
ing to the invention, alginate can be produced using A. vine-
landii, A. chroococcum, P. putida, P. mendocina, P. fluore-
sced, P. maltophilia, P. cepacia, P. mallei, P. pseudomallei, P. 
alcaligenes, P. stutzeri, P. putrefacients, P. acidovorans, P. 
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diminuta or P. aeruginosa strains. In one preferred embodi- 	 show increased activity. The invention includes, for example, 
ment of the invention, alginate is produced using P. aerugi- 	 bacteria that express C1pP, C1pP2 and/or C1pX proteins that 
nosa. 	 show increased protease activity as compared to wild-type 
In some embodiments, the invention provides for methods 	 C1pP, C1pP2 and/or C1pX proteins. 
of producing alginate by culturing bacteria with at least one 5 	 In some embodiments, the bacteria used to produce algi- 
genetic alteration that results in increased alginate produc- 	 nate have about a 1.5 fold, a 2 fold, a 3 fold, a 4 fold, 5 fold or 
tion. In some embodiments, the genetic alteration results in 	 about a 10 fold increase in MucE, C1pP, C1pP2 and/or C1pX 
the increased activity of a positive regulator of alginate pro- 	 activity compared to wild-type bacteria. In some embodi- 
duction compared to wild-type bacteria. For example, the 	 ments, the bacteria used to produce alginate express MucE, 
present invention provides for methods of producing alginate io C1pP, C1pP2 and/or C1pX protein at about 1.5 fold, 2, fold, 3 
by culturing bacteria that have increased A1gU, MucE, C1pP, 	 fold, 4 fold, 5 fold or about 10 fold higher level than wild-type 
C1pP2 and/or C1pX activity. In some embodiments of the 	 bacteria. In some embodiments, the bacteria used to produce 
present invention, positive regulators of alginate production 	 alginate express MucE, C1pP, C1pP2 and/or C1pX proteins 
can be overexpressed from an exogenous DNA source, e.g., 	 that are about 1.5 fold, 2 fold, 3 fold, 4 fold, 5 fold or about 10 
from plasmid DNA. For example, plasmids containing 15 fold more stable than in wild-type bacteria. In some embodi- 
sequences encoding for C1pP, C1pP2, and/or C1pX can be 	 ments, the bacteria used to produce alginate express MucE, 
expressed to increase alginate production in bacteria. In other 	 C1pP, C1pP2 and/or C1pX proteins and are about 1.5 fold, 2 
embodiments of the present invention, positive regulators of 
	
fold, 3 fold, 4 fold, 5 fold or about 10 fold more stable than 
alginate can be overexpressed from an endogenous DNA 	 wild-type bacteria. In some embodiments, the bacteria used 
source, due to the alteration of endogenous regulatory 20 to produce alginate are about 1.5 fold, 2 fold, 3 fold, 4 fold, 5 
sequences. For example, mutations in regulatory sequences 	 fold or about 10 fold more stable than wild-type bacteria. 
such as promoters or enhancers that result in overexpression 	 In another embodiment of the invention, the bacteria 
of a positive regulator or underexpression of a negative regu- 	 express lower levels or activity of factors that negatively 
lator of alginate production are contemplated. Additionally, 	 regulate the production of alginate. For example, the present 
mutations in regulatory sequences on exogenous DNA 25 invention provides for methods of producing alginate by cul- 
sources are also contemplated. 	 turing bacteria that have decreased MucA, MucB, MucD 
In one embodiment of the present invention, the bacteria 	 and/or KinB activity. In some embodiments of the present 
used to produce alginate have increased MucE activity com- 	 invention, the activity of negative regulators of alginate pro- 
pared to wild-type bacteria. The activity of MucE can be 	 duction is reduced by decreased levels of production, by 
increased using any technique known in the art. For example, 3o decreased levels of activity, and/or by decreased levels of 
MucE may be overexpressed by providing an exogenous 	 stability. Alterations that result in decreased activity include 
mucE gene, for example, on a plasmid. Alternatively, endog- 	 mutations that result in alterations in protein coding 
enous mucE may be overexpressed, for example, by increas- 	 sequences, e.g. mutations that result in premature termination 
ing the strength of the mucE promoter or by increasing the 	 codons and/or mutations that result in nonfunctional proteins 
stability of the MucE protein. Another aspect of the present 35 and/or mutations that delete the gene completely. Alterations 
invention is to provide methods for producing alginates in 	 that result in decreased activity include mutations that affect 
bacteria wherein the bacteria overexpress a protease that 	 regulator sequences and reduce transcription or translation of 
negatively regulates MucA, for example, C1pP, C1pP2 and/or 	 factors that negatively regulate the production of alginate. 
C1pX. 	 Alternations that result in decreased activity also include 
In another embodiment of the present invention, the bac-  40 exposure to RNAi or other treatments that decrease levels of 
teria used to produce alginate have increased activity of one or 	 factors that negatively regulate the production of alginate. 
more positive regulators of alginate production. For example, 	 In another embodiment of the invention, the bacteria used 
bacteria of the present invention may have increased MucE 	 to produce alginate will have decreased MucD activity and 
and C1pP activity, MucE and C1pP2 activity, or MucE and 
	
decreased A1gW activity as compared to wild-type bacteria. 
C1pX activity. 	 45 In some embodiments, the bacteria used to produce alginate 
In another embodiment of the present invention, the bac- 	 have about a 1.5 fold, a 2 fold, a 3 fold, a 4 fold, a 5 fold or 
teria used to produce alginate express a positive regulator of 	 about a 10 fold decrease in MucD and/or A1gW activity as 
alginate production under the control of an inducible system. 	 compared to wild-type bacteria. In some embodiments, the 
For example, the bacteria of the present invention may con- 	 bacteria will have decreased MucD activity and a deletion in 
tain mucE, c1pP, c1pP2 and/or clpX under the control of an 5o A1gW (no AlgWactivity),In other embodiments, the bacteria 
inducible promoter, e.g. an arabinose-inducible promoter or 	 will have a deletion in MucD (no MucD activity) and 
an IPTG-inducible promoter, such that levels of MucE, C1pP, 	 decreased A1gW activity. In a preferred embodiment of the 
C1pP2 and/or C1pX and therefore alginate production, 	 invention, alginate can be produced using bacteria with a 
increase in the presence of arabinose (e.g., about 0.5-1% of 	 deletion of both MucD and A1gW. 
arabinose) or IPTG. Other inducible systems which are 55 	 In one embodiment of the invention, the bacteria used to 
known to those of skill in the art can also be used according to 	 produce alginate have a mutation in mucA that results in 
the present invention. 	 production of a truncated MucA protein. The truncation may 
In some embodiments, the invention provides for the pro- 	 be, for example, the result of an insertion, deletion or amino 
duction of alginate by culturing bacteria that express an over- 	 acid change that results in a premature termination codon. 
active protein that is a positive regulator of alginate produc-  6o The truncation may, for example, be a C-terminal deletion. A 
tion. An overactive protein has greater activity than the 	 C-terminal deletion may result, for example, in a MucA pro- 
corresponding wild-type protein in the same condition. The 	 tein of between about 20 and 160 amino acids in length, 20 
activity can be, for example, increased protease activity or 	 and 140 amino acids in length, 20 and 120 amino acids in 
increased kinase activity. For example, the present invention 	 length, 20 and 100 amino acids in length, 20 and 75 amino 
contemplates not only bacteria that express increased levels 65 acids in length or between about 20 and 50 amino acids in 
of MucE, C1pP, C1pP2 and/or C1pX proteins, but also bacteria 	 length. A C-terminal deletion may also result in a MucA 
that express mutants of MucE, C1pP, C1pP2 and/or C1pX that 	 protein about 55, 56, 57, 58, 59, 60, 61, 62, 63, 64 or 65 amino 
US 9,175,322 B2 
13 
	
14 
acids in length. In one embodiment, the C-terminal deletion 
results in a MucA protein about 59 amino acids in length. 
In one embodiment of the invention, the bacteria used to 
produce alginate express a MucA protein that lacks one or 
more domains of MucA. In one embodiment, the MucA pro-
tein lacks the transmembrane domain or a portion of the 
transmembrane domain. In another embodiment, the MucA 
protein lacks the transmembrane domain and the periplasmic 
domain. In one embodiment, the MucA protein includes 
about amino acids 1 to 20, 1 to 30, 1 to 40, 1 to 50, 1 to 60, 1 
to 70, 1 to 80, 1 to 84 or about 1 to 90. In one embodiment of 
the invention, the MucA protein includes amino acids 1 to 59. 
In one embodiment of the invention, the MucA protein 
includes about amino acids 1 to 84 and amino acids 104 to 
194. In one embodiment of the invention the MucA protein 
includes a mutation or mutations in the transmembrane 
domain that disrupt MucA protein localization. 
In one embodiment of the invention, the MucA protein or a 
fragment thereof is fused to additional amino acids. The addi-
tional amino acids may be, for example, amino acids from a 
different protein, amino acids from a non-consecutive region 
of MucA or other amino acids sequences. In one embodi-
ment, the additional amino acids are expressed as a result of 
a frameshift mutation. In one embodiment of the invention, a 
frameshift mutation results in a protein about 60, 70, 80, 90, 
100, 125, 150 or about 175 amino acids in length. In one 
embodiment of the invention, a frameshift mutation results in 
a protein about 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or about 
100 amino acids in length. In one embodiment, the frameshift 
mutation results in a protein about 94 amino acids in length. 
In another embodiment of the invention, the bacteria used 
for alginate production have a transposon located upstream of 
the mucA gene. In some embodiments of the invention, the 
bacteria used for alginate production have a transposon 
located in a mucA regulatory region that results in decreased 
production of MucA protein as compared to wild-type. In 
some embodiments of the invention, the transposon insertion 
results in a null allele of mucA. 
In another embodiment of the present invention, the bac-
teria used to produce alginate have decreased activity of at 
least two negative regulators of alginate production. For 
example, bacteria of the present invention may have 
decreased MucA and MucB activity, decreased MucA and 
Mucl) activity, decreased MucB and Mucl) activity, or 
decreased MucA, MucB and Mucl) activity. 
In some embodiments, the bacteria used to produce algi-
nate have about a 1.5 fold, a 2 fold, a 3 fold, a 4 fold, 5 fold or 
about a 10 fold decrease in MucA, MucB, Mucl) and/or KinB 
activity compared to wild-type bacteria. In some embodi-
ments, the bacteria used to produce alginate express MucA, 
MucB, Mucl) and/or KinB protein at about 1.5 fold, 2, fold, 
3 fold, 4 fold, 5 fold or about 10 fold lower level than wild-
type bacteria. In some embodiments, the bacteria used to 
produce alginate express MucA, MucB, Mucl) and/or KinB 
proteins that are about 1.5 fold, 2 fold, 3 fold, 4 fold, 5 fold or 
about 10 fold less stable than in wild-type bacteria. 
In some embodiments of the invention, the bacteria used to 
produce alginate have increased activity of at least one posi-
tive regulator of alginate production and decreased activity of 
at least one negative regulator of alginate production. In one 
embodiment of the invention, alginate can be produced using 
bacteria with decreased MucA activity and increased MucE, 
C1pP, C1pP2 and/or C1pX activity. 
The present invention also provides methods for producing 
alginates in bacteria that lack one or more endogenous endot-
oxin biosynthesis genes. Endotoxin genes are any genes that 
are expressed by bacteria that cause toxicity to eukaryotic 
cells, including, but not limited to, toxicity mediated by the 
endotoxin lipopolysaccharide (LPS). Other toxin genes car-
ried on the so-called "pathogenicity island" or "type III secre-
tion system" are generally repressed in P. aeruginosa during 
5 the overproduction of alginate (Wu, W., et al., J Bacteriol 
186:7575-85 (2004)). However, in some embodiments of the 
invention, these genes can be removed, for example, through 
homologous recombination using a mutant allele cloned into 
the Pseudomonas suicide vector (pEX100T). 
to 	 The present invention also provides methods forproducing 
alginates in bacteria that are stable. By the term "stable bac- 
teria" is meant a bacterial strain that does not revert to a 
non-mucoid phenotype within about 14 days. In addition, 
15 bacterial strains that do not convert to a non-mucoid pheno-
type within about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 
27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 
150,160, 170 orwithin about 180 days are also contemplated. 
In addition, bacterial strains that do not revert to the non- 
20 mucoid phenotype within about 14 to 60 days, 14 to 50 days, 
14 to 40 days, 14 to 30 days, 14 to 20 days, 2-3 months, 2-4 
months, 2-5 months, 2-6 months, 3-4 months, 3-5 months and 
3-6 months are also contemplated. 
In some embodiments of the present invention, the algi- 
25 pate-producing bacteria are grown under certain conditions. 
The bacteria may be grown on agarose plates and/or in liquid 
culture, for example in LB broth. When Pseudomonas is used 
as the alginate-producing bacteria, Pseudomonas Isolation 
Agar (PIA) can be used, which includes IrgasanTM. IrgasanTM 
30 is a potent broad spectrum antibiotic that is not active against 
Pseudomonas. PIA is also useful in isolating Pseudomonas 
aeruginosa from other pseudomonads based on color because 
PIA contains magnesium chloride and potassium sulfate to 
enhance the formation of the blue or blue-green pyocyanin 
35 pigment by Pseudomonas aeruginosa. 
The bacteria of the invention may be grown at a certain 
temperature. For example, the bacteria may be grown at a 
temperature of about 42, 37 or 30° C. In a preferred embodi-
ment, the bacteria are grown at 37° C. 
40 	 The bacteria of the invention can be grown on a solid agar 
surface with a concentration of about 0.8% agarose and 
higher, or in liquid broth. Bacteria can also be grown in a 
regular shake flask in a temperature-controlled incubator or in 
a continuous bioreactor system with temperature, nutrient, 
45 dissolved oxygen and/or pH control. 
In some embodiments of the present invention, the alginate 
is produced by mass production. Mass production includes 
growing and isolating large quantities of alginate, for 
example, by growing bacteria, for example Pseudomonas 
5o aeruginosa, in a bioreactor and purifying alginate from the 
supernatant. In some embodiments, mass production requires 
that the bacterial strains are stable producers of alginate for 
about 14 to 120 days. 
Alginate Testing, Isolation and Purification 
55 	 One skilled in the art will appreciate the various known 
direct and/or indirect techniques for detecting the presence of 
alginate, any of which may be used herein. These techniques 
include, but are not limited to, antibody-based detection 
methods and optical density-based measurements. For 
60 example, alginate-specific antibodies can be used to observe 
the alginate-induced specific fluorescence using an immun-
ofluorescence technique as described, for example by 
Bragonzi, A. et al., J. Infec. Dis. 192:410-9 (2005). In addi-
tion, high-performance liquid chromatography (HPLC) can 
65 be used to measure the components of mannuronate and 
guluronate after a sample is completely hydrolyzed, for 
example by treatment with a strong acid such as sulfuric acid 
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(H2SO4). Phenotypic based assays, for example, identifica-
tion of mucoid phenotypes, are also contemplated in the 
present invention. 
According to the present invention, alginate can be isolated 
and purified using any method known in the art. For example, 
alginate can be purified from bacterial cultures by centrifug-
ing the culture to remove bacterial cells, and then treating the 
alginate-containing supernatant with ethanol or propan-2-ol. 
Furthermore, in another embodiment of the invention, 
CaC12 can be used to remove endotoxic contaminants, such as 
LPS. In certain embodiments of the invention, alginate can be 
precipitated from raw bacterial alginate samples (i.e., the 
supernatant collected after centrifugation to remove bacterial 
cells). In some embodiments, the supernatant sample from 
which alginate is purified contains about 0.01 mg/ml, 0.05 
mg/ml, 0.10 mg/ml, 0.20 mg/ml, 0.50 mg/ml, 1.00 mg/ml or 
about 5.00 mg/ml of alginate. In some embodiments of the 
invention, the supernatant sample from which alginate is 
purified contains about 0.01 to 0.10 mg/ml, 0.01 to 0.20 
mg/ml, 0.01 to 0.50 mg/ml, 0.01 to 1.00 mg/ml or about 0.01 
to 5.00 mg/ml of alginate. In some embodiments of the inven-
tion, the supernatant sample from which alginate is purified 
contains about 0.05 to 0.10 mg/ml, 0.05 to 0.20 mg/ml, 0.05 
to 0.50 mg/ml, 0.05 to 1.00 mg/ml or about 0.05 to 5.00 
mg/ml. In one embodiment of the invention, the alginate 
concentration is about 0.1 mg/ml. 
In other embodiments of the invention, alginate can be 
prepared from bacterial cultures in which alginate is present 
at a concentration of about 10 µg/ml protein, 20 µg/ml protein, 
30 µg/ml protein, 40 µg/ml protein, 50 µg/ml protein, 60 
µg/ml protein, 70 µg/ml protein, 80 µg/ml protein, 90 µg/ml 
protein, 100 µg/ml protein, 150 µg/ml protein, 200 µg/ml 
protein, 250 µg/ml protein, 300 µg/ml protein, 350 µg/ml 
protein, 400 µg/ml protein, 450 µg/ml protein, 500 µg/ml 
protein, 550 µg/ml protein, 600 µg/ml protein or about 1000 
µg/ml protein. In some embodiments of the invention, the 
alginate is present at a concentration of about 10-1000 µg/ml 
protein, 50-500 µg/ml protein, 100-400 µg/ml protein or 
about 200-300 µg/ml protein. In some embodiments of the 
invention, the alginate is present at a concentration of about 
10-500 µg/ml protein, 10-400 µg/ml protein, 10-300 µg/ml 
protein, 10-200 µg/ml protein, 10-100 µg/ml protein or about 
10-50 µg/ml protein. 
In other embodiments, the sample from which alginate is 
purified contains a certain concentration of endotoxin, such as 
LPS. For example, the concentration of endotoxin can be 
about 0.01 mg/ml, 0.05 mg/ml, 0.10 mg/ml, 0.20 mg/ml, 0.30 
mg/ml, 0.40 mg/ml or about 0.50 mg/ml. In some embodi-
ments, the endotoxin concentration is from about 0.01 mg/ml 
to 1.0 mg/ml, 0.05 mg/ml to 1 mg/ml, 0.25 mg/ml to 0.75 
mg/ml or about 0.5 mg/ml to 1.0 mg/ml. In one embodiment 
of the invention, the endotoxin is LPS and the concentration is 
about 0.5 mg/ml. LPS concentrations can be determined 
using any known methods in the art, including, but not limited 
to, Limulus amoebocyte assay and thiobarbituric acid assay. 
In other embodiments of the invention, the concentration of 
CaC12 used to precipitate the alginate is about 0.01 mg/ml, 
0.05 mg/ml, 0.10 mg/ml, 0.25 mg/ml, 0.50 mg/ml,1.0 mg/ml, 
5.0 mg/ml, 10.0 mg/ml, 15 mg/ml or about 20 mg/ml. In other 
embodiments, the concentration of CaC1 2 used to precipitate 
alginate is about 0.01 to 50 mg/ml, 0.05 to 25 mg/ml, 0.05 to 
20 mg/ml, 0.05 to 10 mg/ml, 0.05 to 5 mg/ml, 0.05 to 1 mg/ml, 
0.05 to 0.50 mg/ml or about 0.05 to 0.25 mg/ml. In one 
embodiment, the concentration of CaC1 2 used is about 0.10 
mg/ml. 
In some embodiments, the alginate is free or substantially 
free of endotoxins. As used herein, the term "free of means 
16 
that there are no endotoxins present in the sample. As used 
herein, the term "substantially free" means that the concen-
tration of endotoxin in the sample is below the minimum 
concentration that causes toxicity. In some embodiments, the 
5 alginate is isolated to a specific purity. For example, in some 
embodiments, the alginate is at least 50% pure, at least 60% 
pure, at least 70% pure, at least 80% pure, at least 90% pure, 
at least 95% pure, at least 97% pure, at least 98% pure, at least 
99% pure or at least 99.5% pure. In other embodiments, the 
to alginate isolated is about 50% pure, about 60% pure, about 
70% pure, about 80% pure, about 90% pure, about 95% pure, 
about 97% pure, about 98% pure, about 99% pure or about 
99.5% pure. 
15 Alginate Compositions and Uses 
The present invention provides for biological cultures 
comprising stable mucoid bacteria. According to the present 
invention, biological cultures are compositions comprising 
bacteria. The biological cultures can be liquid, for example in 
20 LB broth, or solid, for example in agarose. The biological 
cultures can be frozen cultures, cultures in stationary phases, 
and/or cultures in growth phases. 
In some embodiments, the present invention also provides 
compositions comprising alginate. In some embodiments, the 
25 compositions comprise alginate produced by bacteria that 
have increased MucE activity as compared to wild-type bac-
teria. In other embodiments, the compositions comprise algi-
nate produced by bacteria that have decreased MucA activity 
as compared to wild-type bacteria. In another embodiment, 
30 the compositions comprise alginate produced by bacteria that 
have a truncation mutation in mucA. In another embodiment, 
the compositions comprise alginate produced by bacteria that 
have a transposon insertion before the mucA gene. The 
present invention also provides for compositions that com- 
35 prise alginate produced by bacteria that have increased pro-
tease activity, for example, increased C1pX, C1pP or C1pP2 
activity. In another embodiment, the composition comprises 
alginate produced by bacteria that have decreased MucA 
activity as compared to wild-type bacteria and increased 
40 C1pX, C1pP and/or C1pP2 activity as compared to wild-type 
bacteria. In another embodiment, the composition comprises 
alginate produced by bacteria that have decreased MucA 
activity as compared to wild-type bacteria, increased MucE 
activity as compared to wild-type bacteria and increased 
45 C1pX, C1pP and/or C1pP2 activity as compared to wild-type 
bacteria. Furthermore, the invention provides compositions 
that comprise alginate produced by bacteria that are stable for 
about 14 to 90 days. In yet another embodiment, the invention 
provides for compositions comprising alginate produced by 
5o bacteria that lack one or more endogenous endotoxin genes. 
The isolated bacterial alginate of the present invention can 
be used as, for example, gelling, thickening, stabilizing, 
swelling, and viscosity imparting agents. Thus, the isolated 
bacterial alginate of the present invention is useful in, for 
55 example, the food, textile, dental, pharmaceutical, cosmetic, 
and paper industries. 
It can serve as a thickening agent in, for example, food 
items, such as ice cream, salad dressing, pet food chunks, low 
fat spreads, sauces and pie filings. Bacterial alginates can also 
6o be used in other diverse applications including for fixation 
and color in textile printing, for improving surface quality in 
paper and board treatments, for improving bendability of 
rods, for increasing aggregate size in flocculation processes in 
water treatment, for forming slits in can sealings, for concen- 
65 trating latex during rubber extraction from plants, for reduc-
ing rates of surface drying in production of ceramics and 
foods, or for immobilization of cells. 
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The isolated bacterial alginate of the present invention can 
also be incorporated into wound dressings to provide a moist 
surface for healing. Alginate fibers trapped in a wound are 
readily biodegraded. Dressings with alginate are used to treat 
ulcers in diabetic patients. Propylene glycol alginate has been 
used as an acid-stable stabilizer for uses such as preserving 
the white fluffy head of foam on beers. Furthermore, the 
bacterial alginates of the present invention can be used to 
sequester cations, such as iron, from solutions, and therefore 
can be useful in filtering systems. Alginate absorbs radioac-
tive elements, heavy metals and free radicals. Because algi-
nate cannot be broken down by bile or saliva and cannot be 
absorbed by the body, it is secreted from the body together 
with the heavy metals and radioactive substances. 
In order to further illustrate the present invention, specific 
examples are set forth below. It will be appreciated, however, 
that these examples are illustrative only and are not intended 
to limit the scope of the invention. 
EXAMPLES 
Materials and Methods 
The following materials and methods apply generally to all 
the examples disclosed herein. Specific materials and meth-
ods are disclosed in each example, as necessary. 
The practice of the present invention will employ, unless 
otherwise indicated, conventional techniques of cell biology, 
cell culture, molecular biology (including PCR), vaccinol-
ogy, microbiology, recombinant DNA, and immunology, 
which are within the skill of the art. Such techniques are 
explained fully in the literature. See, for example, Molecular 
Cloning A Laboratory Manual, 2d Ed., Sambrook et al., ed., 
Cold Spring Harbor Laboratory Press (1989); DNA Cloning, 
Volumes I and II, D. N. Glover ed., (1985); Oligonucleotide 
Synthesis, M. J. Gait ed., (1984); Mullis et al. U.S. Pat. No. 
4,683,195; Nucleic Acid Hybridization, B. D. Flames & S. J. 
Higgins eds. (1984); Transcription And Translation, B. D. 
Flames & S. J. Higgins, eds. (1984); Freshney, R. L, Culture 
OfAnimal Cells, Alan R. Liss, Inc. (1987); Immobilized Cells 
And Enzymes, IRL Press (1986); Perbal, B., A Practical 
Guide To Molecular Cloning (1984); the treatise, Methods In 
Enzymology, Academic Press, Inc., N.Y.; Gene Transfer Vec-
tors For Mammalian Cells, J. H. Miller and M. P. Calos eds., 
Cold Spring Harbor Laboratory (1987); Methods In Enzymol-
ogy, Vols. 154 and 155, Wu et al. eds.; Immunochemical 
Methods In Cell And Molecular Biology, Mayer ,  and Walker,
eds., Academic Press, London, (1987); and in Ausubel et al., 
Current Protocols in Molecular Biology, John Wiley and 
Sons, Baltimore, Md. (1989). Each of the references cited in 
this paragraph is incorporated herein by reference in its 
entirety. 
Strains and Plasmids 
E. coli DHSa was used as the host for molecular cloning. 
The E. coli strains were grown in Lennox broth (LB), or LB 
agar supplemented with carbenicillin (100 µg/ml), gentami-
cin (13 µg/ml), tetracycline (15 µg/ml) or kanamycin (40 
µg/ml), when required. P. aeruginosa strains were grown at 
37'C. (unless specified) in LB broth, LB agar and Pseudomo-
nas Isolation Agar (PIA, Difco) plates (supplemented with 
300 µg/ml of gentamycin or carbenicillin, when required). 
The parental strains of P. aeruginosa for conjugation were 
grown at 42° C. in LB broth. 
Transformation, Conjugation, Transposon Mutagenesis and 
Complementation Analysis 
Either electroporation or a chemical transformation 
method was used for the transformation of E. coli. A standard 
Pseudomonas conjugation protocol was followed with the 
following modifications. E. coli SM10 Xpir carrying pFAC 
and P. aeruginosa strains were grown in 2 ml LB broth over-
night at 37' C. and 42° C., respectively. The cell density of the 
5 cultures was measured by optical density at 600 nm and 
adjusted to aratio of 1:1, which was equivalent to 8x10 $ cells 
for matings. The mixed cultures were incubated on LB plates 
for 6 h at 37° C. The cells were harvested and washed in LB 
broth. The final cell mixtures in a volume of 1 ml were spread 
io on 8 PIA plates (50 ml each) supplemented with gentamicin. 
The conjugal pairs were incubated at 37° C. for 24 h for 
selection and screening exconjugants with a mucoid colony 
morphology. Such mutants were isolated and purified a mini-
mum of 3 times. Mutants were frozen in 10% skim milk in a 
15 —80° C. freezer. 
Biparental conjugations were carried out for transposon 
mutagenesis, using the pFAC carrying E. coli SM10 Xpir as 
the donor strain and PAO581 as recipient strain. After 4-6 hrs 
of mating of P. aeruginosa and E. coli cells on LB plates at 37' 
20 C., bacteria were streaked onto PIA plates supplemented with 
300 µg/ml of gentamycin. Non-mucoid colonies were sub-
jected to further genetic analyses. The chromosomal DNA of 
non-mucoid mutants was prepared by using the QIAamp 
genomic DNA kit. About two micrograms of DNA was 
25 digested by Sall overnight at 37° C., followed by purification 
and self-ligation using Fast-Link DNA ligase (Epicentre). 
The circular closed DNA was used for inverse PCR using 
GM30UT and GM50UT primers designed based on the gen-
tamycin resistance gene and the PCR products were purified 
3o and sequenced. Triparental conjugations, using pRK2013 as 
the helperplasmid, were conducted for genetic manipulations 
of P. aeruginosa PA0581 and PAOI strains. 
Pulsed-Field Gel Electrophoresis (PFGE) and Southern 
Hybridization 
35 PFGE coupled with southern hybridization analyses were 
applied for the genome organization comparison between P. 
aeruginosa PAO581 and PAOI as previously described. 
Southern blot hybridization was also applied to monitor the 
copy number of transposon insertion using the gentamycin 
4o resistance gene (Gm'") as the probe template. 
Western Blot Analyses 
Western blots were performed according to the following 
protocol. The bacterial cells were harvested from LB broth 
(supplemented with 150 µg/ml of carbenicillin and 5 mM of 
45 IPTG). The cell density at 600 nm (OD...) was measured and 
equal amounts of bacterial cells for each sample were pel-
leted. The bacterial cells were washed with cold PBS buffer 
(pH 7.4) once and then pelleted for protein extraction. The 
total cellular protein extracts were prepared using 
5o ReadyPrepsTM kit (Epicentre). Protein samples were heated at 
95° C. for 5 min, electrophoresed on an SDS-PAGE gel (15% 
acrylamide), and transferred onto a nitrocellulose membrane 
(pore size 0.1 µm, Schleicher & Schnell). Immunoblots were 
developed by using rat anti-HA monoclonal antibody 
55 (Roche) or rabbit anti-RNAP (RNA polymerase a-subunit) 
polyclonal antibody (Courtesy by M. J. Chamberlin, UC-
Berkely) as the primary antibody, and Horseradish peroxi-
dase-labeled goat anti-rat (Roche) or anti-Rabbit IgG 
(Kirkegaard & Perry laboratories) as the secondary antibody. 
6o Enhanced chemiluminescence ECL (Amersham Bio-
sciences) was used for detection. 
(3-galactosidase Activity Assay 
Assays were based on the method as originally described 
by Miller (In Experiments in Molecular Genetics, J. H. 
65 Miller, ed., Cold Spring Harbor Laboratory, Cold Spring Har- 
bor, N.Y. (1972), pp. 352-355) with the following modifica- 
tion. The cells of NHl-3 were grown on PIA plates in tripli- 
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cate for 24 hat 37'C. The cells were harvested in PBS and cell 
density was measured by OD 600 . Samples were assayed after 
SDS/chloroform permeabilization of the cells. 
The P. aeruginosa strains carrying the Pl,zgu promoter-
lacZ fusion were grown on PIA plates in triplicate at 37° C., 
and were harvested and resuspended in cold PBS buffer. The 
optical density at 600 nm was recorded and the P-galactosi-
dase activity was measured after SDS/chloroform penneabi-
lization for each sample. The Miller unit is equivalent to 
1000*(A420/_L75 *A55o/OD ... /ml/min), where A 420 and 
A551 is the absorbance at 420 mn and 550 mu, respectively. 
The experiments were carried out in triplicate at least three 
times. 
Nucleotide Sequence Accession Number 
The annotated nucleotide sequence of algUmucABCD in 
PA0581 was submitted to the NCBI and assigned the Gen-
Bank accession number, EF635219. 
DNA Manipulations 
Two steps ofpolymerase chain reaction (PCR)-based clon-
ing were used for general cloning purposes. First, the target 
genes were amplified by high-fidelity PCR using the appro-
priate primer sets containing the built-in restriction sites fol-
lowed by cloning into pCR4-TOPO. The DNA fragments 
were digested by restriction enzymes, gel-purified, and trans-
ferred to the shuttle vector pUCP20. All recombinant plas-
mids were sequenced to verify the absence of mutations with 
M13 universal forward and reverse primers using an ABI 
3130 Genetic Analyzer at the Marshall University School of 
Medicine Genomics Core Facility. PCR reactions were per-
formed with MasterAmpTM Taq DNA Polymerase (Epicen-
tre) in 50 ld EasyStart PCR tubes (Molecular BioProducts) as 
previously described (Head, N. E., and H. Yu, Infect. Immun. 
72:133-44 (2004)). 
Inverse PCR (iPCR) 
The mariner transposon and its junction region in pFAC 
were sequenced. A multiple cloning site (MCS) was identi-
fied immediately outside the Y end of the gentamicin cassette 
within the transposon. To map the insertion site, an iPCR 
protocol was developed to utilize this convenient MCS. 
Pseudomonas genomic DNA was purified using a QIAamp 
genomic DNA kit. The DNA concentration was measured 
using the NanoDrop® ND-1000 spectrophotometer (Nano-
Drop Technologies). Two µg DNA was digested by restriction 
enzymes Sall or PstI at 37° C. overnight followed by gel 
purification. The fragmented DNA was ligated to form the 
circularly closed DNA using the Fast-LinkTM DNA ligation 
kit (Epicentre). A volume of 1 µl ligated DNA was used as 
template for PCR using GM50UT and GM30UT according to 
the condition as follows, 94° C. for 1 min, 34 cycles consist-
ing of 94° C. for 1 min, 58° C. for 2 min, and 72° C. for 2 min, 
and a final extension step consisting of 72° C. for 8 min. After 
PCR, the products were analyzed on a 1% agarose gel. The 
PCR products were purified using the QIAquick PCR purifi-
cation kits and sequenced using GM50UT as described 
above. 
Alginate and Protein Assays 
The alginate assay was based on a previously published 
method (Knutson, C. A., and A. Jeans, Anal. Biochem. 
24:470-481 (1968)) with the following modifications. P. 
aeruginosa and mutants were grown on 50 ml PIA plates in 
triplicate for a period of 72 h. At various time points, bacterial 
growth was removed from plates and re-suspended in 40 ml 
phosphate-buffered saline (PBS; pH 7.4). The optical density 
at 600 nm (OD 600)  was recorded. The alginate standard curve 
was made using D-mannuronic acid lactone (Sigma) in the 
range of 0-100 µg/ml. To measure the protein concentration, 
the cells in PBS were lysed in 1:1 ratio with 1 M NaOH for 15 
20 
min. The protein assay was performed using the Bio-Rad D, 
Protein Assay kit. The range for protein standard (bovine 
serum albumin) curve was from 0.2 to 1.2 mg/ml. 
RNA Isolation and RT-PCR 
5 	 P. aeruginosa strains PAO1, VE2 and VE3 were grown on 
50 ml PIA plates for 24 h at 37° C. The cells were harvested 
in 40 ml PBS and re-suspended based on OD 600 to produce a 
cell population of 109 to 10 10 . Total RNA was isolated using 
a RiboPureTM-Bacteria Kit (Ambion) followed by DNase 
10 treatment as supplied. The quality of RNA was evaluated on 
an Agilent 2100 bioanalyzer. RT-PCR was performed using a 
One-Step RT-PCR kit (Qiagen). One µg bacterial RNA was 
reverse-transcribed into cDNA at 50° C. for 30 min followed 
by PCR amplification: 94° C. for 15 min, 34 cycles consisting 
15 of 94° C. for 1 min, 58° C. for 2 min, and 72° C. for 2 min. The 
PCR products were analyzed on 1% agarose gel, and the 
intensity of bands was analyzed on a Typhoon 8600 Variable 
Mode Imager (Molecular Dynamics) with the ImageQuant (v. 
5.2) Software. 
20 Monoclonal Antibodies 
The A1gU and MucB monoclonal antibodies used in the 
Examples are from previously published sources (Boucher et 
al., J. Bacteriol. 178:511-523 (1996); Schurr et al., J. Bacte-
riol. 178:4997-5004 (1996)) with a low level of cross-reac- 
25 tivity. The specificities of these antibodies are appropriate 
because the a1gU and mucB negative strains failed to display 
the respective A1gU and MucB proteins. Furthermore, two 
non-specific proteins of 50 kDa and 75 kDa from MucB and 
A1gU blots respectively were used as convenient internal 
30 controls to normalize the protein levels. 
Southern Hybridization 
A 754 by PCR product was amplified from accl of 
pUCP30T using GM-F and GM-R primers, which was puri-
fied via gel extraction and labeled with digoxygenin as 
35 described by the manufacturer (Roche Molecular Biochemi-
cals). Agarose gels were soaked in 0.25 N HCl for 30 min, 
rinsed in H2O, soaked in 1.5 M NaCl/0.5 M NaOH for 30 min 
and 1.5 M NaCl/0.5 M Tris-Cl, pH 8.0 for 30 min. A blotting 
apparatus (BIO-RAD Vacuum Blotter) was used with a filter 
40 paper wick, a Hybond-N+ membrane (Amersham Pharmacia 
Biotech), and transferred with l0xSSC transfer buffer for 2 h. 
After transfer, the membrane was rinsed in transfer buffer and 
UV cross-linked. Hybridization was done using the DIG High 
Prime DNA Labeling and Detection Starter Kit II (Roche 
45 Applied Science) and labeled probe described above. 
Statistical Analysis 
Analysis of alginate production P-galactosidase activity 
was done with one-way analysis of variance (ANOVA) fol-
lowed by pairwise multiple comparisons with Holm-Sidak 
50 method. Analysis of normalized protein intensity was carried 
out with the means of each group in comparison with that of 
PAOI using t test assuming unequal variance or ANOVA if 
multiple groups were compared. All analyses were performed 
with SigmaStat (v. 3.1, Systat Software) and SigmaPlot (v. 
55 9.0, Systat Software) software. 
Example 1 
Mariner-Based Transposon Mutagenesis Approach to 
60 	 Identify Mucoid Mutants in P. aeruginosa 
To investigate alginate regulation in P. aeruginosa, the 
versatile Tcl/mariner himarl transposon carried on pFAC 
(GenBank Accession number DQ366300), a Pseudomonas 
65 suicide plasmid, was used to mutagenize the non-mucoid 
strains of P. aeruginosa coupled with a genetic screen for 
mucoid mutants. (The screen and results which are summa- 
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rized in this example are described in detail in International 	 variant) (Fyfe, J. A. M. & Govan, J. R. W., Progress in indus- 
PCT Published Application WO 2007/123721, published 	 trial microbiology, pp. 45-83 (M. E. Bushell ed., Elsevier 
Nov. 1, 2007, which is herein incorporated by reference in its 	 1983)), it was first determined whether there were large 
entirety.) The mutant phenotype for selection was mucoid, 	 genomic alterations in this strain. Using macrorestriction 
alginate-overproducing colony morphology. Colonies were 5 digestions of the genome coupled with separation by pulse 
grown on the Pseudomonas Isolation Agar (PIA), which 	 field gel electrophoresis, no large-scale recombination, inver- 
includes IrgasanTM, a potent broad spectrum antimicrobial 	 sion, deletion, or amplifications were noted in PA0581 as 
that is not active against Pseudomonas (IrgasanTM is a trade- 	 compared to PAOI I. This is consistent with earlier data (Fyfe, 
mark of Ciba-Geigy). 	 J. A. M. & Govan, J. R. W., Progress in industrial microbiol- 
The sequence of the Tcl/mariner himarl transposon was 10 ogy, pp. 45-83 (M. E. Bushell ed., Elsevier 1983)) which 
analyzed, and the nucleotide sequence of the transposon in 	 indicated that the mucoid phenotypes associated with muc 
pFAC has been deposited in GenBank with the accession no. 	 mutation(s) designated muc-22, muc-23, and muc-25 are not 
DQ366300 (1473 bp, Tcl/himarl mariner transposon vector 	 associated with major changes in the DNA organization. 
pFAC). The schematic diagram of the mariner transposon 	 Previously, the muc-25 locus of PA0581 was roughly 
region within pFAC is shown in FIG. 1A. The fact that mari-  15 mapped to the region between pruAB (67.5 min) and hisI (69 
ner transposon was flanked by a region containing six unique 	 min), very close to the algUmucABCD cluster (68 min) 
restriction enzyme sites allowed for the development of an 	 (Fyfe, J. A. M. & Govan, J. R. W., Progress in industrial 
efficient inverse PCR procedure that was used to rapidly map 	 microbiology, pp. 45-83 (M. E. Bushell ed., Elsevier 1983)). 
transposon insertions in the genome. 	 Therefore, the algUmucABCD genes of PA0581 were 
Many of the transposon insertions that were identified in 20 sequenced. A single base deletion at T180 of mucA was 
the screen fell into three genomic regions, algU-mucABCD 
	
identified, leading to creation of a premature stop codon 
(FIG. 113), mucE (FIG. 1C) and a1gB-kinB (FIG. 1D). 	 (TGA) at 285. The resulting frameshift encoded a truncated 
Mucoid mutants identified in the screen were tested for algi- 	 protein of 94 amino acids, which includes the N-terminal 59 
nate production (FIGS. 2 and 3). The highest producer of 	 amino acids ofwild-type MucA and 35 divergent amino acids 
alginate isPA01-VE3 (FIG.2C),Inthis strain, the transposon 25 due to the frameshift (FIG. 9). This protein was probably 
inserted in a TA dinucleotide in front of mucA, but in an 	 located in the cytoplasm due to the absence of the transmem- 
opposite direction of mucA transcription (FIG. 113). This 	 brane (MucA84_lo4)  and periplasmic (MucA113-170)  domains. 
configuration of transposon insertion caused a loss of mucA 
	
No mutation was found in the a1gU, mucB, mucC, and 
transcription because the P, m promoter is stronger than the 	 mucD genes of PA0581. To determine if this mutation could 
promoters of algU mucABC operon since VEl insertion is 30 be identified in naturally-occurring mucoid P. aeruginosa 
mucoid (FIG. 213) and caused an elevation of A1gU expres- 	 isolates, the a1gU-mucA genes were sequenced in a series of 
sion. The PAOI -VE3 strain produces large amounts of algi- 	 variant mucoid isolates obtained from the lungs of transgenic 
nate over a period of 72 hr such that plates are dripping due to 	 CF mice which emerged after 6-12 months of chronic lung 
alginate production. However, PAOI-VE3 reverts to the non- 	 infection (Coleman, F. T., et al., Proc Nad Acad Sci USA 
mucoid phenotype within about 3-4 days. 	 35 100:1949-1954 (2003)). Interestingly, the same mucA muta- 
Transposon insertions in the promoter region of mucE 	 tion as that of PA0581 was identified in one of the mucoid 
(VE2) and in the coding region of kinB (VE13) also resulted 	 isolates. The wild-type (wt) mucA gene in PA01 was 
in mucoid phenotypes. As shown in FIG. 3, alginate produc- 	 replaced with the mucAAT180 allele from PA0581 and the 
tion was increased in these strains as well. 	 resultant strain, PAOI DRl, became mucoid, as expected. The 
Another producer of large amounts of alginate contains a 40 mucoid phenotype of both PA0581 and PAOI DRl could be 
transposon in the algU mucABCD region. This is PA01- 	 suppressed by the introduction of wt mucA in trans on a 
VE12 (mucD mutant). Compared to PAOl-VE3, PA01- 	 plasmid (pUCP20T-mucA) (lac promoter). Thus, the previ- 
VE12 is a more stable producer of alginate. The transposon 	 ously uncharacterized muc-25 mutation was due to deletion 
mutants in FIG. 113-11) carrying mutations in the mucD gene 	 of a single base of T180 in the mucA gene and has been 
(DRB, VE19, VE14, andVE12) are more stable producers of 45 designated the mucA25 allele. 
alginate than the mucA mutants (V4, VI and VE3), mucE 
(VE2) and kinB mutants (VE13). The non-mucoid revertants 	 Example 3 
with the suppressor mutations can be readily isolated in VE3 
and VE2 after 3-4 days at 37° C. whereas no non-mucoid 
	 Transposon Insertions in fig, c1pP, clpX, and c1pP2 
mucD mutants have been isolated yet. The non-mucoid VE3 50 	 Render the muc-25 Mucoid PA0581 Non-Mucoid 
mutants carry mutations that inactivate or attenuate the activ- 
ity of algU with the nucleotide sequences of VE3-NMI -4 as 	 To determine if other factors might be important for the 
described in International PCT Published Application WO 	 expression of the mucoid phenotype in PA0581, we used an 
2007/123721. 	 approach of mariner transposon mutagenesis, which gives 
55 rise to high-density insertion of a TA-flanked gentamicin 
Example 2 	 resistance marker into the chromosome of target bacteria 
including P. aeruginosa (Qiu, D., et al., Proc Nad Acad Sci 
Identification of the muc-25 Mutation as a Single 	 USA 104:8107-8112 (2007); Rubin, E. 7., et al., Proc Nad 
Base Deletion AT180 in mucA 
	
Acad Sci USA 96:1645-1650 (1999); Wong, S. M. and Mekal- 
6o anos, 7.7., Proc Natl Acad Sci USA 97:10191-10196 (2000)). 
Another mucoid variant, PA0581, was also analyzed. 	 In total, 86 non-mucoid mutants were isolated out of about 
PA0581 is a stable mucoid strain and does not easily revert to 	 100,000 Gm" mutants of PA0581 screened. Insertion sites 
a non-mucoid phenotype. PA0581 was isolated in vitro fol- 	 were identified by inverse PCR and sequencing. The majority 
lowing the incubation of the non-mucoid P. aeruginosa PAO 	 of the non-mucoid mutants harbored a single insertion as 
with phage E79 (Fyfe, J. A. M. & Govan, J. R. W., Journal of 65 confirmed by Southern hybridization using the Gm" cassette 
General Microbiology 119, 443-450 (1980)). Since this strain 	 as a probe. As expected, most insertions were mapped to the 
carried undefined muc mutation(s) (designated as the muc-25 	 known positive regulatory genes including a1gU, algR (Der- 
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etic, V., et al., J Bacteriol 171, 1278-1283 (1989)), algB 
(Goldberg, J. B. & Dahnke, T., Mol Microbiol 6:59-66 
(1992)), and amrZ (algZ) (Baynham, P. J. & Wozniak, D. J., 
Mol Microbiol 22:97-108 (1996); Tart, A. H., et al., JBacte-
riol 187:7955-7962 (2005)). These results, while confirming 
the previous findings, also validated the reliability and effi-
ciency of the mariner-based transposon mutagenesis. There 
were about 2 to 3 independent transposon insertions in the 
first 7 genes of the 18 kb alginate biosynthetic operon, algD 
(PA3540), alg8 (PA3541), alg44 (PA3542), algK (PA3543), 
algE (PA3544), algG (PA3545), and algX (PA3546), as well 
as the unlinked algC (PA5322) gene. However, there were no 
insertions found in the other 5 genes, algL (PA3547), algI 
(PA3548), algJ (PA3549), algF (PA3450) and algA (PA3551). 
These results were consistent with previous findings, since 
transposon inactivation of algL is only possible if the tran-
scription of the entire algD operon was suppressed (Jain, S. & 
Ohman, D. E., Infectimmun 73:6429-6436 (2005)) and inac-
tivation of algI, algJ, and algF would not lead to a complete 
loss of mucoidy as these genes encode proteins involved in 
alginate acetylation, but not biosynthesis (Franklin, M. J., et 
al., JBacteriol 186:4759-4773 (2004)). 
Other transposon insertions in the non-mucoid mutants 
mapped to the tig-clpP-clpX (PA1800-1802) polycistronic 
loci and a monocistronic locus of PA3326, a paralogous gene 
of c1pP (designated c1pP2). The c1pP2 gene encodes a 
polypeptide of 201 amino acids, homologous to C1pP (en-
coded by PA1801, 213 amino acids). Eleven out of the fifty-
one transposon insertions (21.6%) were mapped to the tig (2 
insertions), c1pP (3), clpX (4), and c1pP2 (2) loci. Southern 
blot analyses confirmed that only a single copy of the trans-
poson was inserted into the chromosome in these null 
mutants. The relevance of these genes to the mucoid conver-
sion was confirmed by complementation tests. The mucoid 
phenotype and alginate synthesis could be restored to the tig 
(PAO581DR23), c1pP (PAO581DR58), and clpX 
(PAO581DR45) null mutants by the pUCP20T borne tig-
c1pP-clpX (pUCP20T-tig-clpXP) in trans (FIGS. 4 and 8). In 
addition, introduction of pUCP20-clpP2 could restore 
mucoidy to the c1pP2 null mutants of PAO58IDR3 and 
PAO58IDR9, suggesting that the C1pP2 protease is also 
required for the mucoid phenotype (FIGS. 4 and 8). However, 
the non-mucoid phenotype of the tig null mutants, 
PA0581 DR23 and PA0581 DR6, seemed to result from polar 
effects of the transposon insertion on the downstream c1pP 
and clpX since pUCP20T-tig did not restore alginate synthe-
sis (PAO581DR23) (FIGS. 4 and 8). Both pUCP20T-tig-
clpXP and pUCP20T-clpXP induced a high level of alginate 
production in the tig mutant, PAO58IDR23. To confirm the 
function of C1pXP and to verify that the transposon insertion 
did not cause other unknown mutations, we cloned the GmR  
interrupted allele of PA0581DR58 (clpP::Ge) into the sui-
cide vector pEX100T and used it to disrupt the c1pP gene of 
PAO581. The resultant c1pP mutant of PAO581 was non-
mucoid, and the mucoid phenotype could be complemented 
by the plasmid borne c1pP in trans. 
Since the tig-clpP-clpX gene cluster was identified to be 
involved in the regulation of alginate synthesis, the tig-clpP-
clpX cluster of PA0581 was subjected to sequence analyses. 
Compared with the tig-clpP-clpX cluster of the parental non-
mucoid strain of PAOI, some missense mutations were 
found, suggesting that these polymorphisms could be 
required for the mucoid phenotype of PA05 81. Therefore, the 
tig-clpXP and clpXP genes of PAO581 were cloned into 
pUCP20T to test for the mucoid induction in PAOl . However, 
over-expression of these PA0581-derived genes, tig-clpXP 
(PA0581), clpXP (PA0581) or the c1pP2 gene from PA0581 
(pUCP20T-clpP2), was not sufficient to cause the mucoid 
conversion in PAOL Furthermore, plasmid-borne alleles 
24 
from PAO581 were able to restore the mucoid phenotype of 
the non-mucoid mutants PAO581DR58 (clpP::GmR), 
PA581DR23 (tig::GmR), PAO581DR45 (clpX::Gm R) and 
PAO58IDR3 (c1pP2::GmR). The pUCP20T-tig-clpXP genes 
5 from PAOI could also complement in trans the null mutations 
of fig, clpX, and c1pP in PAO581 (results were identical to 
what was seen with PAO581-derived alleles). These results 
indicate that the polymorphisms of the tig-clpXP loci were 
not responsible for the mucoid conversion in PAO581, and 
10 represented functional allelic variants that likely arose when 
PAOI was mutagenized to produce the mucoid variant of 
PAO581 or during the laboratory passages of PAO581. 
Example 4 
15 
A1gU Activity is Significantly Decreased in the c1pP, 
clpX, and c1pP2 Null Mutants 
A1gU activity was assayed in various strains, including 
20 PAOI, PAO581, and the isogenic null mutants of fig, clpX, 
c1pP, and c1pP2 as well as two other non-mucoid strains with 
mutations in a1gU (PAO581DR7) or algR (PAO581DR51). 
The P  promoter of a1gU has been reported to be an A1gU-
dependent autoregulatory promoter (Firoved, A. M. & Der-
efic, V., JBacteriol 185:1071-1081 (2003); Schurr, M. J., et 
25 al., JBacteriol 177:5670-5679 (1995)). ThePl,,g,promoter-
lacZ fusion was integrated into the CTX phage attachment 
site (attB) on the bacterial chromosome of PAO581 and the 
isogenic mutants (Hoang, T. T., et al., Plasmid 43:59-72 
(2000)). A1gU expression was 2.2 fold higher in PAO581 than 
30 that in the wt non-mucoid strain PAOI (P<0.001 ANOVA, 
P<0.05 Dunnett's test) thus validating that the mucoid phe-
notype of PAO581 was caused by the increased level of func-
tional A1gU (FIG. 5). Furthermore, A1gU activity of the 
isogenic, non-mucoid fig, clpX, c1pP, and c1pP2 null mutants 
35 of PAO581 was comparable to that of PAOI, and was 2-3 fold 
lower than that of PAO581 (P<0.001 ANOVA, P<0.05 Dun-
nett's test for pair-wise comparisons). 
Very low level of the (3-galactosidase activity was detected 
in the a1gU null mutant PAO58IDR7 (negative control), 
40 
which was 2.8-fold and 6-fold lower than PAOI and PAO581, 
respectively (data not shown). The A1gU activity was 
decreased slightly in the algR null mutant PAO581DR51 
(positive control) but was 1.8-fold higher than that of PAOI 
(data not shown). A1gR is an A1gU-dependent downstream 
regulatory gene for alginate synthesis (Deretic, V., et al., J 
45 Bacteriol 171:1278-1283 (1989)), and its disruption could 
not affect the activity of the upstream regulator A1gU. These 
results suggest that C1pX, C1pP and C1pP2 are involved in the 
increase in A1gU activity, which is associated with increased 
alginate synthesis and the subsequent development of the 
50 mucoid phenotype. 
Example 5 
Over-Expression of a1gU Restores the Mucoid 
55 	 Phenotype to the fig, c1pP, clpX, and c1pP2 Null 
Mutants of PAO581 
The above results suggest that the tig and clp mutants could 
not degrade the anti-o factor MucA protein to release A1gU, 
thus producing the non-mucoid phenotype in P. aeruginosa. 
60 If this is the case, over-expression of A1gU in these mutants 
should bypass the requirement for fig, c1pP, clpX, and c1pP2. 
Therefore, the pUCP20T-P BA D algU construct was intro- 
duced into these null mutants. All of these conjugants con- 
verted to the mucoid phenotype when inoculated onto PIA 
65 plates supplemented with 0.5-2.5% of arabinose, whereas in 
the absence of arabinose the strains remained non-mucoid on 
PIA plates. These results suggest that the endogenous A1gU is 
US 9,175,322 B2 
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The in vivo stability of MucA protein was monitored by 
Western blot analysis ofthe HA-tagged wt-MucA protein and 45 
HA-tagged MucA25 proteins in wt PAOI and mucoid variant, 
PA0581. Similar levels of wt HA-MucA fusion protein (-25 
kDa) could be detected in PAOL PA0581 and the tig-clp 
mutants of PA0581 (data not shown), suggesting that the 
full-length HA-tagged MucA protein is stable in all of these 50 
genetic backgrounds. However, the levels of the truncated 
MucA25 (-15 kDa) proteins was 4.3-fold lower in PAO1 
compared with PA0581 after the arabinose induction (FIG. 
5). The levels of HA-tagged MucA25 proteins were also 
25 
sequestered by the truncated MucA25 protein in the fig, c1pX, 
c1pP, and c1pP2 null mutants of PA0581 as these cofactors are 
apparently needed for release of A1gU from the anti-sigma 
factor MucA. 
Example 6 
Both Truncated MucA Proteins and Intact 
tig-clpP-clpX and c1pP2 are Required for the Mucoid 
Phenotype in P. aeruginosa 
To determine if the conversion of P. aeruginosa to the 
mucoid phenotype is dependent on both a truncated MucA 
protein and the Clp proteases that could degrade the cytoplas-
mic portion of this sequestering anti-sigma factor, the HA 
tagged mucA25 and HA tagged wt mucA fusions were cre-
ated in the pBAD/pUCP20T vector, and the constructs were 
transferred into PAOL PA0581, PA581DR23 (tig::Gm R), 
PA0581DR45 (c1pX::Ge), PA051DR58 (c1pP::Ge), and 
PA0581DR3 (clpP2::GmR). As expected, there was no phe-
notypic change in wt PAOI expressing HA-tagged muc25. 
However, over-expression of the mucA25 allele suppressed 
the mucoid phenotype in PA0581, while the vector control 
had no effects. Similarly, all of PA0581 strains carrying wt 
mucA allele in trans remained mucoid when arabinose was 
absent, but converted to non-mucoid when the level of arabi-
nose was >0.01%. Similarly, the IPTG-inducible pVDtac24-
based construct pDR206, carrying the HA tag-mucA fusion, 
and pDR207, carrying an HA tag-mucA22 fusion, could also 
suppress the mucoid phenotype of PA0581 under the IPTG 
induction. However, higher levels of inducers (>0.05% of 
arabinose or 5 mM of IPTG) were required for the mucA25 or 
mucA22 carrying constructs to suppress the mucoid pheno-
type of PA0581 as compared to the amount needed for the 
mucoid suppression by the wt mucA carrying constructs. 
These results indicate that the mucoid phenotype of PA0581 
is due to the truncation of anti-o factor MucA as a conse-
quence of mucA25 mutation and that C1pXP might be respon-
sible for degrading the N-terminus of MucA. 
Example 7 
Truncated N-Terminal MucA Proteins are Stabilized 
in the fig, clpX, c1pP, and c1pP2 Null Mutants 
26 
increasedintheclp-mutants of PA0581 compared with PAOI 
(FIG. 5). The level of HA-tagged MucA25 was >3-fold 
higher in PA0581DR3 (c1pP2::Gm R) and PA0581DR58 
(clpP::GmR) than inPA0581 (FIG. 5). There was an accumu- 
5 lation of the MucA25 variant protein under the condition of 
arabinose induction in the null mutants of fig, clpX, c1pP and 
c1pP2 (FIG. 5). Therefore, in the absence of the C1pXP pro-
tease, MucA25 was not degraded, suggesting that this pro-
tease complex may be responsible for the degradation of the 
N-terminus of MucA25 to release the sequestered A1gU into 
to the cytoplasm for activating the transcription of alginate bio-
synthetic genes. As shown in Table 1, mutations in c1pP and 
c1pX prevent a mucoid phenotype in a clinical strain CF24. 
TABLE 1 
15 
Disruption of clpP and clpX in CF24  
pUCP20T pUCP20T- 
Strain Genotype Phenotype vector clpPX 
CF24 Clinical isolate Mucoid Mucoid 
20 CF24DR1 CF24 clpP::Gm-" Non-mucoid Non-mucoid Mucoid 
CF24DR2 CF24 clpX::Gm' Non-mucoid Non-mucoid Mucoid 
Example 8 
25 
Characterization of Alginate Produced from Bacteria 
To compare alginate produced in bacteria to that produced 
in seaweed, alginate purified from P. aeruginosa and a com-
mercially available seaweed alginate were analyzed. In these 
experiments, two bacterial strains were used, PAOI-VE19 
(mucD mutant) and PA0578 (PAOI -mucA22) for the prepa-
ration of bacterial alginate. Bacteria were first grown at 37° C. 
on 50 ml PIA plates for 24-48 hours. Bacterial growth was 
removed from plates with PBS and suspended in a total vol-
ume of 50 ml PBS per plate. Bacterial suspensions were 
centrifuged to remove the cellular debris and pellets. The 
supernatants were precipitated with three volumes of cold 
ethanol, freeze-dried and resuspended in 10 ml PBS, and 
dialyzed in a large volume of cold PBS to remove the salts. 
VE19-1 alginate was dialyzed while VE19-2 was not-dia-
lyzed. Seaweed alginate used was purchased from Sigma 
Aldrich as alginic acid (A-7003) extracted from Macrocystis 
pyrifera (Kelp). 
The alginates were analyzed using the Viscotek Triple 
Detector System (Houston, Tex.), which makes use of four 
different technologies: Gel Permeation Chromatography 
(GPC), Flow Injection Polymer Analysis (FIPA), Dilute Solu-
tion Viscosity (DSV) and Dynamic Light Scattering (DLS). 
The analysis demonstrated that the physical properties of 
bacterial alginate are different from those of seaweed algi-
nates. The data are summarized below in Table 2 and show, in 
particular, that the bacterial alginates are much more viscous 
than seaweed alginates. 
TABLE 2 
Physical analysis ofthree purified alginate samples produced by P. aeruginosa as 
compared to the seaweed alginates. 
Cale. 
Sample MW Viscosity Hydrodynamic Reflection % Cone. 
ID (daltons) (dL/g) radius (nm) index Recovery (mg/ml) 
VE19-1 13,415,000 96.8 274 0.15 395 1.08 
VE19-2 14,815,000 97.3 283 0.15 365 0.82 
PA0578 18,605,000 97.6 306 0.15 399 0.44 
Seaweeds 77,753 2.2 14 0.15 296 1.87 
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Example 9 
Purification of Alginate with CaC1 2 
28 
Example I I 
Genetic Construction of Alginate Producing Strain 
HDIOI 
When produced in bacteria, alginate samples can be con-
taminated with a major cell wall component of bacteria, 
lipopolysaccharide (LPS). LPS is a known endotoxin which 
can cause septic shock and inflammation. As a result, removal 
of LPS from alginate preparations to be used for example, in 
food or pharmaceutical compositions, is needed. Raw bacte-
rial alginate samples (i.e., the supernatants that were collected 
after centrifugation to remove bacterial cells) were treated 
with calcium chloride. A concentration of 0.1 mg/ml CaC1 2 
solution was sufficient to precipitate alginate at a concentra-
tion of 0.1 mg/ml. In contrast, P. aeruginosa lipopolysaccha-
ride (L9143, Sigma-Adrich) at a concentration of 0.5 mg/ml 
could not be precipitated with a solution of 20 mg/ml CaCl2- 
These results indicate that alginate can be precipitated from 
solution by CaC12 using conditions under which LPS does not 
precipitate. This allows for effective removal of LPS from 
bacterially produced alginates. 
Example 10 
P. aeruginosa MucE Caused Conversion to Mucoidy 
in P. fluorescens 
Other Pseudomonas species have mucE homologs (FIG. 
7). In order to determine if mucE of P. aeruginosa is func-
tional in other Pseudomonas species, P. aeruginosa mucE 
was expressed in P. fluorescens. In these experiments, P. 
aeruginosa mucE was cloned into an arabinose-inducible 
vector, pHERD20T, which was created by replacing the P,,, 
promoter in pUCP20T with the PBAD  promoter and araC gene 
from pBAD/Thio-TOPO (Invitrogen(k). The arabinose-in-
ducible mucE construct was transferred into P. fluorescens 
Pf-5 via conjugation. The P. fluorescens carrying the mucE 
construct remained non-mucoid on gentamicin (300 µg/ml) 
supplemented PIA plates and converted to a mucoid pheno-
type in the presence of 0.5-1% of arabinose. These results 
indicate that expression of P. aeruginosa MucE can cause 
conversion to mucoidy in other Pseudomonas strains. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 12 
<210> SEQ ID NO 1 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 1  
5 
Strain HDI01 will be constructed by a "clean" deletion of 
the mucD gene from P. aeruginosa PAOIAalgW (FIG. 10). 
We previously observed that inactivation of mucD with the 
pFAC transposon causes alginate overproduction. However 
10 
alginate production by this strain is not stable and nonmucoid 
revertants can readily occur. We also noted that inactivation of 
the algW gene in the mucD mutant produced copious 
amounts of alginate with a low level of nonmucoid revertants. 
This strain displayed high sustained production of alginate 
(stable mucoid mutant). 
15 	 A1gW and MucD control alginate production through over- 
lapping and divergent pathways. When MucD is absent, algi-
nate production occurs due to loss of quality control in the 
envelope. A1gW has a role in the degradation of an anti-sigma 
factor known as MucA. When MucA is degraded, the master 
20 regulatorAlgU activates alginate production. Our data shows 
the algW/mucD double mutant has a lower rate of MucA 
degradation. This lower rate causes stable and controlled 
alginate production that is not detrimental to the organism. 
To generate HDIOI, a vector will be constructed and 
25 named pEXI00T-AmucD. Through several rounds of PCR 
amplification and subcloning a section of DNA will be gen-
erated with the upstream and downstream flanks near mucD 
but lacking the mucD coding sequence. The plasmid will be 
transferred to PAOIAalgW and selected for antibiotic resis-
tance. Because the deletion vector lacks the Pseudomonas 
30 
origin of replication, the DNA will be taken up by the organ-
ism and incorporated into the genome by homologous recom-
bination. This strain will be resistant to the backbone antibi-
otic but will be sensitive to sucrose due to the presence of the 
sacB gene, which when expressed in the presence of sucrose 
35 kills the organism. The strain will be grown for several hours 
in nutrient rich media lacking antibiotics. DNA recombina-
tion will take place and mucoid strains will be selected that 
are sensitive to the antibiotic and resistant to sucrose. To 
confirm the mucD gene has been deleted, PCR amplicon 
40 sequencing and complementation analysis with mucD 
expressed from pHERD 20T-mucD will be performed. Strain 
HDIOI produces high amounts of alginate and remains 
stable. Furthermore, as this genetic manipulation will be per-
formed by gene deletion without leaving antibiotic resistance 
markers behind, this strain can be further modulated to pro-
duce different types of alginate. 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
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30 
-continued 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 2 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 2 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 3 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 3 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 4 
<211> LENGTH: 89 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas aeruginosa 
<400> SEQUENCE: 4 
Met Gly Phe Arg Pro Val Ser Gin Arg Leu Arg Asp Ile Asn Leu Gin 
1 	 5 	 10 	 15 
Ala Leu Gly Lys Phe Ser Cys Leu Ala Leu Val Leu Gly Leu Glu Ser 
20 	 25 	 30 
Val Ser His Pro Ala Gly Pro Val Gin Ala Pro Ser Phe Ser Gin Gly 
35 	 40 	 45 
Thr Ala Ser Pro Ser Phe Ala Thr Pro Leu Gly Leu Asp Gly Pro Ala 
50 	 55 	 60 
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32 
-continued 
Arg Ala Arg Ala Glu Met Trp Asn Val Gly Leu Ser Gly Ala Val Ser 
65 	 70 	 75 	 80 
Val Arg Asp Glu Leu Arg Trp Val Phe 
85 
<210> SEQ ID NO 5 
<211> LENGTH: 79 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas fluorescens 
<400> SEQUENCE: 5 
Met Asn Ser Ala Leu Leu Leu Leu Asn Ala Ile Ala Ile Ala Val Leu 
1 	 5 	 10 	 15 
Ala Ala Phe His Phe Gin Pro Ala Asp Asp Ala Ala Pro Gly Gly Thr 
20 	 25 	 30 
Ser Phe Ala His Tyr Gin Gin Arg Leu Ala Pro Gin Leu Ala Val Met 
35 	 40 	 45 
Asn Thr Gin Ile Glu Pro Gly Ser Val Thr Arg Val Thr Gin Gly Lys 
50 	 55 	 60 
Ala Ser Gin Gin Pro Ala Ala Ala Pro Thr Glu Arg Trp Val Phe 
65 	 70 	 75 
<210> SEQ ID NO 6 
<211> LENGTH: 75 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas fluorescens 
<400> SEQUENCE: 6 
Met Asn Ser Ala Leu Val Phe Ala Asn Ala Ile Ala Leu Ala Val Leu 
1 	 5 	 10 	 15 
Met Gly Phe His Leu Val Pro Glu Asp Asn Glu Lys Val Ala Gly Arg 
20 	 25 	 30 
Met Pro His Tyr Leu Gin Val Gin Lys Ala Pro Gin Trp Ala Val Leu 
35 	 40 	 45 
Ser Asp Gin Ser Phe Ala Pro Gin Ala Val Ser Gin Ser Glu Gin Ala 
50 	 55 	 60 
Leu Pro Ala His Ser Thr Glu Arg Leu Val Phe 
65 	 70 	 75 
<210> SEQ ID NO 7 
<211> LENGTH: 79 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas syringae 
<400> SEQUENCE: 7 
Met Asn Lys Thr Leu Ser Val Leu Asn Ala Ala Ala Leu Val Ala Leu 
1 	 5 	 10 	 15 
Val Ala Phe His Phe His Asp Ser Gly Ala Ser Asp Thr Gin Val Asn 
20 	 25 	 30 
Ala Pro Ala Pro Val His His Gin Ile Ser His Ala Pro Gin Leu Ala 
35 	 40 	 45 
Ile Met Thr Asp Arg Ile Ala Ser Ala Ala Val Leu Ala Asn Asp Asp 
50 	 55 	 60 
Asp Asp Ser Leu Gin Met Pro Arg Ala Glu Gin Arg Trp Ile Phe 
65 	 70 	 75 
US 9,175,322 B2 
33 
	
34 
-continued 
<210> SEQ ID NO 8 
<211> LENGTH: 79 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas syringae 
<400> SEQUENCE: 8 
Met Asn Lys Thr Leu Ser Ala Leu Asn Ala Ala Ala Leu Val Ala Leu 
1 	 5 	 10 	 15 
Val Ala Phe His Phe Gin Asp Ser Gly Ala Lys Asp Thr Gin Val Thr 
20 	 25 	 30 
Ala Pro Ala Pro Val His His Gin Ile Ser His Ala Pro Gin Leu Ala 
35 	 40 	 45 
Ile Met Thr Asp Arg Val Ala Ser Ala Ala Val Leu Ala Thr Asp Asp 
50 	 55 	 60 
Asp Ala Ser Val Gin Met Pro Arg Ala Glu Gin Arg Trp Val Phe 
65 	 70 	 75 
<210> SEQ ID NO 9 
<211> LENGTH: 79 
<212> TYPE: PRT 
<213> ORGANISM: Pseudomonas syringae 
<400> SEQUENCE: 9 
Met Asn Lys Thr Leu Ser Ala Leu Asn Ala Ala Ala Leu Val Ala Leu 
1 	 5 	 10 	 15 
Val Ala Phe His Phe Gin Asp Ser Gly Ile Lys Asp Ala Gin Ala Ile 
20 	 25 	 30 
Thr Pro Ala Pro Val His His Gin Ile Ser Gin Ala Pro Lys Leu Ala 
35 	 40 	 45 
Ile Met Thr Asp Arg Val Ala Ser Ala Ala Met Leu Ala Asn Asp Asp 
50 	 55 	 60 
Asp Glu Ser Leu Gin Phe Pro Arg Ala Glu Gin Arg Trp Val Phe 
65 	 70 	 75 
<210> SEQ ID NO 10 
<211> LENGTH: 	 89 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: Pseduomonas mucE consensus sequence 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: 	 (1)..(9) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: 	 (11)..(13) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: 	 (15)..(16) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: 	 (19)..(37) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: 	 (40)..(42) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: 	 (44)..(46) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
US 9,175,322 B2 
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36 
-continued 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (48)..(51) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (53)..(54) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (56)..(67) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (69)..(71) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (73)..(81) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (83)..(83) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION:  
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE: 10 
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Asn Xaa Xaa 
1 	 5 	 10 	 15 
Ala Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
20 	 25 	 30 
Xaa Xaa Xaa Xaa Xaa Gly Pro Xaa Xaa Xaa Pro Xaa Xaa Xaa Gin Xaa 
35 	 40 	 45 
Xaa Xaa Xaa Pro Xaa Xaa Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
50 	 55 	 60 
Xaa Xaa Xaa Ala Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 
65 	 70 	 75 	 80 
Xaa Arg Xaa Glu Xaa Arg Trp Val Phe 
85 
<210> SEQ ID NO 11 
<211> LENGTH: 29 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Inverted repeat region of mariner transposon 
vector 
<400> SEQUENCE: 11 
taacaggttg gctgataagt ccccggtct 
	
29 
<210> SEQ ID NO 12 
<211> LENGTH: 29 
<212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Inverted repeat region of mariner transposon 
vector 
<400> SEQUENCE: 12 
agaccgggga cttatcagcc aacctgtta 	 29 
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What is claimed is: 
1. A biological culture comprising isolated stable mucoid 
Pseudomonas aeruginosa bacteria that produce alginate, 
wherein the bacteria are genetically modified Pseudomonas 
aeruginosa bacteria having increased protease activity of a 
C1pP, C1pP2, or C1pX polypeptide as compared to wild-type 
Pseudomonas aeruginosa bacteria that is the result of trans-
formation of the Pseudomonas aeruginosa bacteria with an 
exogenous DNA encodingthe C1pP, C1pP2, or C1pX polypep-
tide to overexpress the C1pP, C1pP2, or C1pX polypeptide as 
compared to wild-type Pseudomonas aeruginosa bacteria 
and wherein the bacteria further have at least one character-
istic selected from the group consisting of: 
(i) increased positive regulator activity of a MucE polypep-
tide as compared to wild-type Pseudomonas aeruginosa 
bacteria, wherein the increased MucE regulator activity 
is the result of transformation of the Pseudomonas 
aeruginosa bacteria with an exogenous DNA encoding 
the MucE polypeptide to overexpress the MucE 
polypeptide as compared to wild-type Pseudomonas 
aeruginosa bacteria, 
(ii) decreased negative regulator activity of a MucA 
polypeptide as compared to wild-type Pseudomonas 
aeruginosa bacteria, wherein the decreased MucA regu-
lator activity is the result of a transposon insertion in the 
promoter of a mucA gene of the Pseudomonas aerugi-
nosa bacteria, a mutation in the MucA polypeptide that 
results in the MucA polypeptide lacking a portion or all 
of a transmembrane domain, and/or a single base dele-
tion at T180 of the mucA gene of the Pseudomonas 
aeruginosa bacteria, and 
(iii) lack of expression of a lipopolysaccharide do not 
express at least one endotoxin biosynthesis gene. 
38 
2. The biological culture of claim 1, wherein the alginate is 
acetylated and the degree of acetylation is 0.1 to 1.0. 
3. The biological culture of claim 1, wherein the ratio of M 
blocks to G blocks in the alginate is between 1:10 and 10:1. 
5 	 4. The biological culture of claim 1, wherein the molecular 
weight of the alginate is between 500 and 20,000 kD. 
5. A method for producing alginate comprising: (a) cultur-
ing the biological culture of claim 1 to produce alginate; and 
10  (b) isolating the alginate. 
6. The method of claim 5, wherein the Pseudomonas 
aeruginosa bacteria is transformed with a plasmid encoding a 
MucE polypeptide and wherein the MucE polypeptide is 
expressed from the plasmid. 
15 	 7. A biological culture comprising isolated stable mucoid 
Pseudomonas aeruginosa bacteria that produce alginate, 
wherein the bacteria are genetically modified Pseudomonas 
aeruginosa bacteria having increased protease activity of a 
C1pP, C1pP2, or C1pX polypeptide as compared to wild-type 
20 Pseudomonas aeruginosa bacteria that is the result of trans-
formation of the Pseudomonas aeruginosa bacteria with an 
exogenous DNA encodingthe C1pP, C1pP2, or C1pX polypep-
tide to overexpress the C1pP, C1pP2, or C1pX polypeptide as 
compared to wild-type Pseudomonas aeruginosa bacteria. 
25 	 8. The biological culture of claim 1, wherein the stable 
mucoid Pseudomonas aeruginosa bacteria further comprises 
a C-terminal deletion in a MucA polypeptide resulting in the 
MucA polypeptide having 20 to 160 amino acids. 
30 	 9. The biological culture of claim 1, wherein the stable 
mucoid Pseudomonas aeruginosa bacteria are stable for 14 to 
90 days. 
